2022

Whaler, S., Geard, A.F., Poupon-Bejuit, L., Massaro, G., Hughes, M.P., Lalji, K., ...Rahim, A.A. (2022). AAV9-mediated gene therapy in a knock-in mouse model of infantile neuroaxonal dystrophy.
Perera, M.S., Suleman, S., Al Haque, S., Zahn, M., Payne, A., Fawaz, S., ...Franco, M. (2022). Development of a human-based platform to assess adeno-associated viral vector genotoxicity.
Chu, W.S., Desai, R., Privolizzi, R., Karda, R., Owusu-Yaw, B., Waddington, S.N., ...Ng, J. (2022). Evaluation of a novel dopaminergic neuronal promoter design candidate in neonatal mice.
Breuer, J., Morfopoulou, S., Buddle, S., Montaguth, O.T., Atkinson, L., Guerra-Assunção, J.A., ...Lee, J. (2022). Genomic Investigations of Acute Hepatitis of Unknown Aetiology in Children. .
Suleman, S., Payne, A., Bowden, J., Haque, S.A., Zahn, M., Fawaz, S., ...Franco, M. (2022). HIV- 1 lentivirus tethering to the genome is associated with transcription factor binding sites found in genes that favour virus survival. Gene Therapy, doi:10.1038/s41434-022-00335-4
Touramanidou, L., Perocheau, D.P., Timmermand, O.V., Gurung, S., Khalil, Y., Mills, P.B., ...Witney, T.H. (2022). In vivo lentiviral gene therapy restores ureagenesis in the urea cycle defect argininosuccinic aciduria.
Gurung, S., Perocheau, D., Touramanidou, L., Khalil, Y., Mills, P., Waddington, S., ...Siddiqui, S. (2022). In Vivo mRNA Therapy for Argininosuccinic Aciduria.
Ng, J., Privolizzi, R., Rahim, A.A., Kurian, M.A., Waddington, S.N. (2022). Long term correction of Dopamine transporter deficiency syndrome following midbrain gene therapy.
Touramanidou, L., Perocheau, D.P., Gurung, S., Cozmescu, A.C., Counsell, J.R., Waddington, S.N., ...Baruteau, J. (2022). Macrophage inhibitor clodronate enhances liver transduction of lentiviral but not AAV vectors in vivo.
Yeo, J.S.L., Johana, N., Tan, Y.W., Fan, Y.P., Mattar, C., Lai, F., ...Waddington, S.N. (2022). Non-human primate (NHP) models for intrauterine therapy.
Suleman, S., Schrubaji, K., Filippou, C., Ignatova, S., Hewitson, P., Huddleston, J., ...Themis, M. (2022). Rapid and inexpensive purification of adenovirus vectors using an optimised aqueous two-phase technology.. Journal of Virological Methods, 299 doi:10.1016/j.jviromet.2021.114305

2021

Boyle, A.K., Suff, N., Waddington, S.N., Peebles, D. (2021). Cervical Gene Delivery of the Antimicrobial Peptide Human beta Defensin 3 (HBD3) Reduces Perinatal Neuroinflammation in a Mouse Model of Ascending Infection-Associated Preterm Birth..
Ng, J., Barral, S., Barrigon, C.D.L.F., Lignani, G., Erdem, F., Wallings, R., ...Heasman, S. (2021). Gene therapy for Dopamine transporter deficiency syndrome: Infantile Parkinsonism-dystonia.
Massaro, G., Geard, A.F., Liu, W., Coombe-Tennant, O., Waddington, S.N., Baruteau, J., ...Rahim, A.A. (2021). Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development. Biomolecules, 11 (4), 611. doi:10.3390/biom11040611
Ng, J., Barral, S., De La Fuente Barrigon, C., Lignani, G., Erdem, F.A., Wallings, R., ...Heasman, S. (2021). Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism.. Science Translational Medicine, 13 (594), doi:10.1126/scitranslmed.aaw1564
Bates, E., Counsell, J., Alizert, S., Baker, A., Suff, N., Boyle, A., ...Baker, A. (2021). In Vitro and In Vivo Evaluation of Human Adenovirus Type 49 as a Vector for Therapeutic Applications. .
Bates, E., Counsell, J., Alizert, S., Baker, A., Suff, N., Bradshaw, A., ...Parker, A. (2021). In Vitro and In Vivo Evaluation of Human Adenovirus Type 49 as a Vector for Therapeutic Applications. .
Bates, E.A., Counsell, J.R., Alizert, S., Baker, A.T., Suff, N., Boyle, A., ...Baker, A.H. (2021). In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications. Viruses, 13 (8), doi:10.3390/v13081483
Privolizzi, R., Tijani, M., Giardina, E., Cooper, S., Oosterveen, T., Iglesias, J.M., ...Ng, J. (2021). In Vivo Evaluation of Novel Synthetic Promoters for CNS Gene Therapy.
Privolizzi, R., Tijani, M., Giardina, E., Cooper, S., Oosterveen, T., Iglesias, J.M., ...Ng, J. (2021). In Vivo Evaluation of Novel Synthetic Promoters for CNS Gene Therapy.
Touramanidou, L., Perocheau, D.P., Gurung, S., Cozmescu, A.C., Waddington, S.N., Counsell, J.R., ...Baruteau, J. (2021). In vivo lentiviral gene therapy for argininosuccinic aciduria.
Counsell, J.R., De Brabandere, G., Karda, R., Moore, M., Greco, A., Bray, A., ...Waddington, S.N. (2021). Re-structuring lentiviral vectors to express genomic RNA via cap-dependent translation. Methods & Clinical Development, 20 357-365. doi:10.1016/j.omtm.2020.12.005
Baruteau, J., Cunningham, S.C., Yilmaz, B.S., Perocheau, D.P., Eaglestone, S., Burke, D., ...Alexander, I.E. (2021). Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeys. Molecular Therapy - Methods & Clinical Development, 23 135-146. doi:10.1016/j.omtm.2021.09.005

2020

Ng, J., Berti, M., Tijani, M., Diaz, J.A., Waddington, S.N., Abbott, C., ...Karda, R. (2020). AAV9 Gene Therapy Rescue of an eEF1A2 Knockout Mouse Model.
Boyle, A.K., Suff, N., Waddington, S.N., Peebles, D. (2020). Ascending Vaginal Bacterial Infection with Bioluminescent E. coli Induces Perinatal Neuroinflammation in Mice.
Soria, L.R., Gurung, S., De Sabbata, G., Perocheau, D., De Angelis, A., Bruno, G., ...Motta, A. (2020). Beclin-1-mediated activation of autophagy improves proximal and distal urea cycle disorders. EMBO Molecular Medicine, doi:10.15252/emmm.202013158
Suff, N., Rajvinder, K., Diaz, A., Ng, J., Baruteau, J., Perocheau, D., ...Bajaj-Elliott, M. (2020). Cervical gene delivery of the antimicrobial peptide, Human β‐defensin (HBD)-3, in a mouse model of ascending infection-related preterm birth. Frontiers in Immunology, doi:10.3389/fimmu.2020.00106
Suff, N., Rajvinder, K., Diaz, A., Ng, J., Baruteau, J., Perocheau, D., ...Bajaj-Elliott, M. (2020). Cervical gene delivery of the antimicrobial peptide, Human β‐defensin (HBD)-3, in a mouse model of ascending infection-related preterm birth. Frontiers in Immunology, doi:10.3389/fimmu.2020.00106
Diaz, J.A., Geard, A., FitzPatrick, L.M., Delhove, J.M.K.M., Buckley, S.M.K., Waddington, S.N., ...Karda, R. (2020). Continual Conscious Bioluminescent Imaging in Freely Moving Mice.. Methods Mol Biol, 2081 161-175. doi:10.1007/978-1-4939-9940-8_11
Diaz, J.A., Geard, A., FitzPatrick, L.M., Delhove, J.M.K.M., Buckley, S.M.K., Waddington, S.N., ...Karda, R. (2020). Continual Conscious Bioluminescent Imaging in Freely Moving Mice.. Methods Mol Biol, 2081 161-175. doi:10.1007/978-1-4939-9940-8_11
Plotegher, N., Perocheau, D., Ferrazza, R., Massaro, G., Bhosale, G., Zambon, F., ...Szabadkai, G. (2020). Correction: Impaired cellular bioenergetics caused by GBA1 depletion sensitizes neurons to calcium overload (vol 17, pg 315, 2020). CELL DEATH AND DIFFERENTIATION, 27 (8), 2534. doi:10.1038/s41418-020-0525-0
Privolizzi, R., Tijani, M., Giardina, E., Cooper, S., Oosterveen, T., Iglesias, J.M., ...Ng, J. (2020). Development of Novel Synthetic Promoters for CNS Gene Therapy.
Diaz, J.F.A., Counsell, J.R., Berti, M., Morris, G., Buckley, S.M.K., Davidge, J., ...Karda, R. (2020). Dual AAV Gene Therapy for Inherited Childhood Epilepsy, Dravet Syndrome.
Diaz, J.F.A., Counsell, J.R., Berti, M., Morris, G., Buckley, S.M.K., Davidge, J., ...Karda, R. (2020). Dual AAV Gene Therapy for Inherited Childhood Epilepsy, Dravet Syndrome.
Sagar, R., Almeida-Porada, G., Blakemore, K., Chan, J.K.Y., Choolani, M., Götherström, C., ...Porada, C.D. (2020). Fetal and Maternal Safety Considerations for In Utero Therapy Clinical Trials: iFeTiS Consensus Statement.. Mol Ther, doi:10.1016/j.ymthe.2020.10.012
Karda, R., Rahim, A.A., Wong, A.M.S., Suff, N., Diaz, J.A., Perocheau, D.P., ...Martin, N.P. (2020). Generation of light-producing somatic-transgenic mice using adeno-associated virus vectors. Scientific Reports, 10 (1), 2121. doi:10.1038/s41598-020-59075-3
Karda, R., Rahim, A.A., Wong, A.M.S., Suff, N., Diaz, J.A., Perocheau, D.P., ...Martin, N.P. (2020). Generation of light-producing somatic-transgenic mice using adeno-associated virus vectors. Scientific Reports, 10 (1), 2121. doi:10.1038/s41598-020-59075-3
Santos, C., Pai, Y.J., Mahmood, M.R., Leung, K.-.Y., Savery, D., Waddington, S.N., ...Greene, N.D.E. (2020). Impaired folate one-carbon metabolism causes formate-preventable hydrocephalus in glycine decarboxylase-deficient mice. Journal of Clinical Investigation, doi:10.1172/jci132360
Gurung, S., Perocheau, D.P., Amin, H.D., Amin, J., Havilland, C.D., Rees, Z., ...Fougerolles, A.D. (2020). In Vivo Exosome Based Therapy for Liver Inherited Metabolic Disease: ASL Deficiency.
Delhove, J.M., Karda, R., FitzPatrick, L.M., Buckley, S.M.K., Waddington, S.N., McKay, T.R. (2020). Non-invasive somatotransgenic bioimaging in living animals [version 1; peer review: awaiting peer review]. F1000Research, 9 1216. doi:10.12688/f1000research.25274.1
Massaro, G., Hughes, M.P., Whaler, S.M., Wallom, K.-.L., Priestman, D.A., Platt, F.M., ...Rahim, A.A. (2020). Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes.. Hum Mol Genet, doi:10.1093/hmg/ddz317

2019

Diaz, J.F.A., Counsell, J.R., Schorge, S., Berti, M., Davidge, J., Waddington, S.N., Karda, R. (2019). AAV gene therapy approach for the treatment of Dravet syndrome.
Lorvellec, M., Pellegata, A., Maestri, A., Counsell, J., De Coppi, P., Gissen, P., ...Mediavilla, E.A. (2019). Bioreactor grown iPSc derived hepatocyte-like cells for testing liver directed gene therapy.
Whyteside, G., Braae, A., Torrance, V., Kippen, N., Iglesias, J.M., Karda, R., ...Baker, K. (2019). Controlled Gene Expression in the Liver; Design of Constitutive, Inducible and Repressible Synthetic Promoters for use in Gene Medicine and Their In Vivo Validation.
Tijani, M., Privolizzi, R., Oosterveen, T., Iglesias, J.M., Cooper, S., Waddington, S.N., Roberts, M.L. (2019). Development of Novel Promoters for Neurological Gene Therapy.
Privolizzi, R., Tijani, M., Oosterveen, T., Giardina, E., Iglesias, J.M., Cooper, S., ...Ng, J. (2019). Development of novel synthetic promoters for CNS gene therapy.
Baruteau, J., Waddington, S.N. (2019). Fetal gene therapy for neurodegenerative lysosomal storage diseases.. Journal of Inherited Metabolic Disease, doi:10.1002/jimd.12018
Ng, J., Barral, S., Barrigon, C.D.L.F., Lignani, G., Erdem, F.A., Wallings, R., ...Heasman, S. (2019). Gene Therapy for Infantile Parkinsonism.
Buckley, S.M.K., David, A.L. (2019). Gene Therapy: Principles and Clinical Potential. In Fetal Therapy: Scientific Basis and Critical Appraisal of Clinical Benefits. (pp. 540-560). .
Plotegher, N., Perocheau, D., Ferrazza, R., Massaro, G., Bhosale, G., Zambon, F., ...Szabadkai, G. (2019). Impaired cellular bioenergetics caused by GBA1 depletion sensitizes neurons to calcium overload.. Cell Death Differ, doi:10.1038/s41418-019-0442-2
Shangaris, P., Loukogeorgakis, S., Subramaniam, S., Flouri, C., Jackson, L., WANG, W., ...Bakhamis, N. (2019). In Utero Gene Therapy (IUGT) Using GLOBE Lentiviral Vector Phenotypically Corrects the Heterozygous Humanised Mouse Model and Its Progress Can Be Monitored Using MRI Techniques. Scientific Reports,
Almeida-Porada, G., Waddington, S.N., Chan, J.K.Y., Peranteau, W.H., MacKenzie, T., Porada, C.D. (2019). In Utero Gene Therapy Consensus Statement from the IFeTIS. Molecular Therapy, doi:10.1016/j.ymthe.2019.02.015
Suff, N., Karda, R., Antinao-Diaz, J., Buckley, S.M., Waddington, S.N., Peebles, D.M. (2019). Intrauterine Infection is Associated with a Reduced NFKB Response in Murine Neonatal Developing Brains..
Suff, N., Karda, R., Antinao-Diaz, J., Buckley, S.M., Waddington, S.N., Peebles, D.M. (2019). Intrauterine Infection is Associated with a Reduced NFKB Response in Murine Neonatal Developing Brains..
Al-Allaf, F.A., Abduljaleel, Z., Athar, M., Taher, M.M., Khan, W., Mehmet, H., ...Waddington, S. (2019). Modifying inter-cistronic sequence significantly enhances IRES dependent second gene expression in bicistronic vector: Construction of optimised cassette for gene therapy of familial hypercholesterolemia. Non-coding RNA Research, 4 (1), 1-14. doi:10.1016/j.ncrna.2018.11.005
Karda, R., Counsell, J.R., Karbowniczek, K., Caproni, L.J., Tite, J.P., Waddington, N. (2019). Production of lentiviral vectors using novel, enzymatically-produced, linear DNA vectors. Gene Ther, doi:10.1038/s41434-018-0056-1
Shangaris, P., Loukogeorgakis, S.P., Subramaniam, S., Flouri, C., Jackson, L.H., Wang, W., ...Bakhamis, N. (2019). Publisher Correction: In Utero Gene Therapy (IUGT) Using GLOBE Lentiviral Vector Phenotypically Corrects the Heterozygous Humanised Mouse Model and Its Progress Can Be Monitored Using MRI Techniques. Scientific Reports, 9 doi:10.1038/s41598-019-55754-y
Suleman, S., Schrubaji, K., Filippou, C., Ignatova, S., Hewitson, P., Karda, R., ...Themis, M. (2019). Rapid purification of adenovirus vectors avoiding CsCl gradient ultracentrifugation.
Baruteau, J., Khalil, Y., Grunewald, S., Zancolli, M., Chakrapani, A., Cleary, M., ...Gissen, P. (2019). Urea Cycle Related Amino Acids Measured in Dried Bloodspots Enable Long-Term In Vivo Monitoring and Therapeutic Adjustment. Metabolites, 9 (11), 275. doi:10.3390/metabo9110275

2018

Dighe, N.M., Tan, K.W., Tan, L.G., Shaw, S.S.W., Buckley, S.M.K., Sandikin, D., ...Choolani, M. (2018). A comparison of intrauterine haemopoietic cell transplantation and lentiviral gene transfer for the correction of severe β-thalassaemia in a HbbTh3/+ murine model.. Experimental hematology, doi:10.1016/j.exphem.2018.03.006
Dighe, N.M., Tan, K.W., Tan, L.G., Shaw, S.S.W., Buckley, S.M.K., Sandikin, D., ...Choolani, M. (2018). A comparison of intrauterine haemopoietic cell transplantation and lentiviral gene transfer for the correction of severe β-thalassaemia in a HbbTh3/+ murine model.. Experimental hematology, doi:10.1016/j.exphem.2018.03.006
Tordo, J., O'Leary, C., Antunes, A.S.L.M., Palomar, N., Aldrin-Kirk, P., Basche, M., ...Godwin, A. (2018). A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency.. Brain : a journal of neurology, doi:10.1093/brain/awy126
Diaz, J.A., Counsell, J., Morris, G., Buckley, S., Davidge, J., Schorge, S., ...Karda, R. (2018). AAV gene therapy for Dravet Syndrome.
Diaz, J.F.A., Counsell, J.R., Morris, G., Buckley, S.M.K., Davidge, J., Schorge, S., ...Karda, R. (2018). AAV Gene Therapy for Inherited Childhood Epilepsy, Dravet Syndrome.
Diaz, J.F.A., Counsell, J.R., Morris, G., Buckley, S.M.K., Davidge, J., Schorge, S., ...Karda, R. (2018). AAV Gene Therapy for Inherited Childhood Epilepsy, Dravet Syndrome.
Hughes, M., Smith, D., Morris, L., Fletcher, C., Colaco, A., Huebecker, M., ...Henckaerts, E. (2018). AAV9 intracerebroventricular gene therapy improves lifespan and normalises long-term locomotor behaviour in a mouse model of Niemann-Pick type C1 disease.
Hughes, M.P., Smith, D.A., Morris, L., Fletcher, C., Colaco, A., Huebecker, M., ...Henckaerts, E. (2018). AAV9 Intracerebroventricular Gene Therapy Improves Lifespan and Normalises Long-Term Locomotor Behaviour in a Mouse Model of Niemann-Pick Type C1 Disease.
Hughes, M.P., Smith, D.A., Morris, L., Fletcher, C., Colaco, A., Huebecker, M., ...Henckaerts, E. (2018). AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease. Human molecular genetics, doi:10.1093/hmg/ddy212
Perocheau, D., Cunningham, S., Lee, J., Antinao Diaz, J., Waddington, S.N., Gilmour, K., ...Alexander, I.E. (2018). Age-related seroprevalence of antibodies against AAV-LK03 in a UK population cohort.. Human gene therapy, doi:10.1089/hum.2018.098
Baruteau, J., Perocheau, D.P., Hanley, J., Lorvellec, M., Rocha-Ferreira, E., Karda, R., ...Rahim, A.A. (2018). Argininosuccinic aciduria fosters neuronal nitrosative stress reversed by As/ gene transfer. NATURE COMMUNICATIONS, 9 doi:10.1038/s41467-018-05972-1
Baruteau, J., Perocheau, D.P., Hanley, J., Lorvellec, M., Rocha-Ferreira, E., Karda, R., ...Rahim, A.A. (2018). Argininosuccinic aciduria fosters neuronal nitrosative stress reversed by As/ gene transfer. NATURE COMMUNICATIONS, 9 doi:10.1038/s41467-018-05972-1
Suff, N., Karda, R., Antinao Diaz, J., Ng, J., Baruteau, J., Perocheau, D., ...Buckley, S.M.K. (2018). Ascending Vaginal Infection Using Bioluminescent Bacteria Evokes Intrauterine Inflammation, Preterm Birth, and Neonatal Brain Injury in Pregnant Mice. American Journal of Pathology, doi:10.1016/j.ajpath.2018.06.016
Suff, N., Karda, R., Antinao Diaz, J., Ng, J., Baruteau, J., Perocheau, D., ...Buckley, S.M.K. (2018). Ascending Vaginal Infection Using Bioluminescent Bacteria Evokes Intrauterine Inflammation, Preterm Birth, and Neonatal Brain Injury in Pregnant Mice. American Journal of Pathology, doi:10.1016/j.ajpath.2018.06.016
Crompton, E., Ahmed, S.G., Nafchi, N.A.M., Waddington, S.N., Yanez-Munoz, R.J. (2018). CD133-positive cells in prenatal development of human pancreas.
Suff, N., Karda, R., Ng, J., Perocheau, D., Bajaj-Elliott, M., Buckley, S.M.K., ...Peebles, D. (2018). Cervical Gene Delivery of Human Beta-Defensin-3 (HBD-3) Reduces E. coli K1 Ascending Infection and Increases the Proportion of Live Births in Pregnant Mice..
Suff, N., Karda, R., Ng, J., Perocheau, D., Bajaj-Elliott, M., Buckley, S.M.K., ...Peebles, D. (2018). Cervical Gene Delivery of Human Beta-Defensin-3 (HBD-3) Reduces E. coli K1 Ascending Infection and Increases the Proportion of Live Births in Pregnant Mice..
Massaro, G., Mattar, C., Wong, A., Sirka, E., Buckley, S., Herbert, B., ...Heales, S. (2018). Fetal gene therapy for neurodegenerative disease of infants. Nature Medicine, doi:10.1038/s41591-018-0106-7
Massaro, G., Mattar, C., Wong, A., Sirka, E., Buckley, S., Herbert, B., ...Heales, S. (2018). Fetal gene therapy for neurodegenerative disease of infants. Nature Medicine, doi:10.1038/s41591-018-0106-7
Counsell, J.R., Karda, R., Diaz, J.A., Carey, L., Wiktorowicz, T., Buckley, S.M.K., ...Almeida, F. (2018). Foamy Virus Vectors Transduce Visceral Organs and Hippocampal Structures following In Vivo Delivery to Neonatal Mice. Molecular Therapy - Nucleic Acids, 12 626-634. doi:10.1016/j.omtn.2018.07.006
Counsell, J.R., Karda, R., Diaz, J.A., Carey, L., Wiktorowicz, T., Buckley, S.M.K., ...Almeida, F. (2018). Foamy Virus Vectors Transduce Visceral Organs and Hippocampal Structures following In Vivo Delivery to Neonatal Mice. Molecular Therapy - Nucleic Acids, 12 626-634. doi:10.1016/j.omtn.2018.07.006
Jeyabalan, J., Munye, M., Castro, S., Chawda, M., Rahim, A., Waddington, S., ...Hernandez-Hernandez, V. (2018). Gene Therapy Restores Normal Weight in a Obese Bardet-Biedl Syndrome 1 (BBS1) Mouse Model.
Karda, R., Rahim, A.A., Suff, N., Diaz, J.A., Perocheau, D.P., Martin, N.P., ...Henckaerts, E. (2018). Generation of Light-Producing Somatic-Transgenic Mice Using Adeno-Associated Virus Vector.
Karda, R., Rahim, A.A., Suff, N., Diaz, J.A., Perocheau, D.P., Martin, N.P., ...Henckaerts, E. (2018). Generation of Light-Producing Somatic-Transgenic Mice Using Adeno-Associated Virus Vector.
Crompton, E., Ahmed, S.G., Nafchi, N.A.M., Waddington, S.N., Yanez-Munoz, R.J. (2018). Integration-deficient lentiviral vectors for in utero gene therapy in spinal muscular atrophy.
Massaro, G., Perocheau, D., Cuka, S., Hughes, M., Karlsson, S., Cheng, S., ...Rahim, A. (2018). Intravenously administered gene therapy for Neuronopathic Gaucher disease.
FitzPatrick, L.M., Hawkins, K.E., Delhove, J.M.K.M., Fernandez, E., Soldati, C., Bullen, L.F., ...Bolaños, J.P. (2018). NF-κB Activity Initiates Human ESC-Derived Neural Progenitor Cell Differentiation by Inducing a Metabolic Maturation Program. Stem Cell Reports, doi:10.1016/j.stemcr.2018.03.015
Motherwell, W.B., Zard, S.Z. (2018). Preface. PERGAMON-ELSEVIER SCIENCE LTD.
Edey, L.F., Georgiou, H., O'Dea, K.P., Mesiano, S., Herbert, B.R., Lei, K., ...MacIntyre, D. (2018). Progesterone, the maternal immune system and the onset of parturition in the mouse.. Biology of Reproduction, doi:10.1093/biolre/iox146
Counsell, J., Karda, R., Diaz, J.A., Meng, J., Vink, C., Morgan, J., ...Howe, S. (2018). The Composition of Lentiviral Vector 5 ' Leader Sequences Can Affect Their Therapeutic Efficacy.
Chan, J.K.Y., Gil-Farina, I., Johana, N., Rosales, C., Tan, Y.W., Ceiler, J., ...Schmidt, M. (2018). Therapeutic expression of human clotting factors IX and X following adeno-associated viral vector-mediated intrauterine gene transfer in early-gestation fetal macaques.. FASEB Journal, fj201801391R. doi:10.1096/fj.201801391R
Crompton, E.M., Ahmed, S.G., Nafchi, N.A.M., Waddington, S.N., Yanez-Munoz, R.J. (2018). Using integration-deficient lentiviral vectors as a therapeutic strategy for spinal muscular atrophy.

2017

Diaz, J.A., Counsel, J., Buckley, S., Schorge, S., Davidge, J., Waddington, S., Karda, R. (2017). A gene therapy approach to Dravet Syndrome.
Suff, N., Karda, R., Buckley, S.M.K., Tangney, M., Waddington, S.N., Peebles, D., Peebles, D. (2017). A Light-Producing Mouse Model of Ascending Vaginal Infection-Related Preterm Birth..
Suff, N., Karda, R., Buckley, S.M.K., Tangney, M., Waddington, S.N., Peebles, D., Peebles, D. (2017). A Light-Producing Mouse Model of Ascending Vaginal Infection-Related Preterm Birth..
Perocheau, D., Baruteau, J., Waddington, S., Cunningham, S., Lisowski, L., Alexander, I., Gissen, P. (2017). Assessment of the Immunogenicity Against AAV with the LK03 Chimeric Capsid Variant in the Human Population.
Delhove, J.M.K.M., Karda, R., Hawkins, K.E., FitzPatrick, L.M., Waddington, S.N., McKay, T.R. (2017). Bioluminescence Monitoring of Promoter Activity In Vitro and In Vivo.. In (pp. 49-64). .
Suff, N., Karda, R., Bajaj-Elliott, M., Tangney, M., Ward, T.H., Peebles, D., ...Waddington, S.N. (2017). Cervical gene delivery of human beta-defensin 3 prevents ascending infection in pregnant mice.
Suff, N., Karda, R., Bajaj-Elliott, M., Tangney, M., Ward, T.H., Peebles, D., ...Waddington, S.N. (2017). Cervical gene delivery of human beta-defensin 3 prevents ascending infection in pregnant mice.
Suff, N., Karda, R., Bajaj-Elliott, M., Buckley, S.M.K., Tangney, M., Waddington, S.N., Peebles, D. (2017). Cervical Gene Delivery of Human Beta-Defensin-3(HBD-3) Prevents Ascending Bacterial Infection in Pregnant Mice..
Suff, N., Karda, R., Bajaj-Elliott, M., Buckley, S.M.K., Tangney, M., Waddington, S.N., Peebles, D. (2017). Cervical Gene Delivery of Human Beta-Defensin-3(HBD-3) Prevents Ascending Bacterial Infection in Pregnant Mice..
Ahmed, S.G., Waddington, S.N., Boza-Moran, M.G., Yanez-Munoz, R.J. (2017). Complete Transduction of Spinal Cord Motor Neurons by Intra-Uterine Delivery of Integration-Deficient Lentiviral Vectors.
Karda, R., Perocheau, D.P., Suff, N., Ng, J., Delhove, J.M.K.M., Buckley, S.M.K., ...Johnson, M.R. (2017). Continual conscious bioluminescent imaging in freely moving somatotransgenic mice.. Sci Rep, 7 (1), 6374. doi:10.1038/s41598-017-06696-w
Karda, R., Perocheau, D.P., Suff, N., Ng, J., Delhove, J.M.K.M., Buckley, S.M.K., ...Johnson, M.R. (2017). Continual conscious bioluminescent imaging in freely moving somatotransgenic mice.. Sci Rep, 7 (1), 6374. doi:10.1038/s41598-017-06696-w
Karda, R., Karbowniczek, K., Caproni, L., Waddington, S.N., Tite, J. (2017). Creation of lentivirus vectors using novel DNA constructs.
Baruteau, J., Waddington, S.N., Alexander, I.E., Gissen, P. (2017). Delivering efficient liver-directed AAV-mediated gene therapy.. Gene Therapy, doi:10.1038/gt.2016.90
Hughes, M., Smith, D., Morris, L., Smith, C., Colaco, A., Huebecker, M., ...Waddington, S. (2017). Development of gene therapy for Niemann-Pick Type C disease.
Vink, C.A., Counsell, J.R., Perocheau, D.P., Karda, R., Buckley, S.M.K., Brugman, M.H., ...Waddington, S.N. (2017). Eliminating HIV-1 Packaging Sequences from Lentiviral Vector Proviruses Enhances Safety and Expedites Gene Transfer for Gene Therapy.. Molecular Therapy, doi:10.1016/j.ymthe.2017.04.028
Vink, C.A., Counsell, J.R., Perocheau, D.P., Karda, R., Buckley, S.M.K., Brugman, M.H., ...Waddington, S.N. (2017). Eliminating HIV-1 Packaging Sequences from Lentiviral Vector Proviruses Enhances Safety and Expedites Gene Transfer for Gene Therapy.. Molecular Therapy, doi:10.1016/j.ymthe.2017.04.028
Alonso-Ferrero, M.E., van Til, N.P., Bartolovic, K., Mata, M.F., Wagemaker, G., Moulding, D., ...Milsom, M.D. (2017). Enhancement of mouse hematopoietic stem/progenitor cell function via transient gene delivery using integration-deficient lentiviral vectors. Experimental hematology, doi:10.1016/j.exphem.2017.09.003
Baruteau, J., Jameson, E., Morris, A.A., Chakrapani, A., Santra, S., Vijay, S., ...Murphy, E. (2017). Expanding the phenotype in argininosuccinic aciduria: need for new therapies.. J Inherit Metab Dis, doi:10.1007/s10545-017-0022-x
Winckelmans, K., Buckinx, R., Waddington, S., Timmermans, J.-.P. (2017). Foetal Intraperitoneal AAV8 Injections as a Valid and Promising Tool to Specifically Target Neuronal Subpopulations Within the Gastrointestinal (GI) Tract.
Baruteau, J., Waddington, S.N., Alexander, I.E., Gissen, P. (2017). Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.. Journal of inherited metabolic disease, doi:10.1007/s10545-017-0053-3
Ahmed, S.G., Waddington, S.N., Boza-Morán, M.G., Yáñez-Muñoz, R.J. (2017). High-efficiency transduction of spinal cord motor neurons by intrauterine delivery of integration-deficient lentiviral vectors.. Journal of controlled release : official journal of the Controlled Release Society, doi:10.1016/j.jconrel.2017.12.029
Shangaris, P., Loukogeorgakis, S., Jackson, L., Wang, W., Blundell, M., Liu, S., ...Schmidt, M. (2017). In utero gene therapy (IUGT) using GLOBE Lentiviral vector phenotypically corrects the heterozygous humanized mouse model and its progress can be monitored using MRI techniques.
Mattar, C.N.Z., Gil-Farina, I., Rosales, C., Johana, N., Tan, Y.Y.W., McIntosh, J., ...Choolani, M. (2017). In Utero Transfer of Adeno-Associated Viral Vectors Produces Long-Term Factor IX Levels in a Cynomolgus Macaque Model. Molecular Therapy, doi:10.1016/j.ymthe.2017.04.003
Massaro, G., Perocheau, D., Cuka, S., Hughes, M.P., Baker, R., Karlsson, S., ...Rahim, A.A. (2017). Intravenously administered gene therapy for the treatment of neuronopathic Gaucher Disease.
Counsell, J.R., Asgarian, Z., Meng, J., Ferrer, V., Vink, C.A., Howe, S.J., ...Morgan, J.E. (2017). Lentiviral vectors can be used for full-length dystrophin gene therapy. SCIENTIFIC REPORTS, 7 doi:10.1038/srep44775
Counsell, J.R., Asgarian, Z., Meng, J., Ferrer, V., Vink, C.A., Howe, S.J., ...Morgan, J.E. (2017). Lentiviral vectors can be used for full-length dystrophin gene therapy (vol 7, 44775, 2017). SCIENTIFIC REPORTS, 7 doi:10.1038/srep46880
Counsell, J.R., Asgarian, Z., Meng, J., Ferrer, V., Vink, C.A., Howe, S.J., ...Morgan, J.E. (2017). Lentiviral vectors can be used for full-length dystrophin gene therapy.. Sci Rep, 7 (1), 79. doi:10.1038/s41598-017-00152-5
Delhove, J.M., Buckley, S.M., Perocheau, D.P., Karda, R., Arbuthnot, P., Henderson, N.C., ...McKay, T.R. (2017). Longitudinal in vivo bioimaging of hepatocyte transcription factor activity following cholestatic liver injury in mice.. Scientific Reports, 7 41874. doi:10.1038/srep41874
Delhove, J.M., Buckley, S.M., Perocheau, D.P., Karda, R., Arbuthnot, P., Henderson, N.C., ...McKay, T.R. (2017). Longitudinal in vivo bioimaging of hepatocyte transcription factor activity following cholestatic liver injury in mice.. Scientific Reports, 7 41874. doi:10.1038/srep41874
Counsell, J.R., Vink, C.A., Karda, R., Perocheau, D.P., Brugman, M.H., Buckley, S.M., ...Howe, S.J. (2017). LTR1 Vectors Enhance Safety in Gene Therapy and Can Be Exploited for Rapid, Transient Gene Delivery.
Counsell, J.R., Vink, C.A., Karda, R., Perocheau, D.P., Brugman, M.H., Buckley, S.M., ...Howe, S.J. (2017). LTR1 Vectors Enhance Safety in Gene Therapy and Can Be Exploited for Rapid, Transient Gene Delivery.
Cuka, S., Ng, J., Seino, K., Hughes, M., Massaro, G., Waddington, S., ...Rahim, A. (2017). Novel Therapeutic Strategies in NBIA: A Gene Therapy Approach for PLA2G6-Associated Neurodegeneration.
Baruteau, J., Perocheau, D.P., Hanley, J., Rocha-Ferreira, E., Karda, R., Ng, J., ...Prunty, H. (2017). Rescue and Phenotypic Correction in Argininosuccinate Lyase-Deficient Mice by AAV8.ASL Transfer.
Baruteau, J., Perocheau, D.P., Hanley, J., Rocha-Ferreira, E., Karda, R., Ng, J., ...Prunty, H. (2017). Rescue and Phenotypic Correction in Argininosuccinate Lyase-Deficient Mice by AAV8.ASL Transfer.
Suff, N., Waddington, S.N. (2017). The power of bioluminescence imaging in understanding host-pathogen interactions.. Methods (San Diego, Calif.), doi:10.1016/j.ymeth.2017.07.001
Hanley, J., Kumar Dhar, D., Mazzacuva, F., Fiadeiro, R., Burden, J.J., Lyne, A.M., ...Virasami, A. (2017). Vps33b is Crucial for Structural and Functional Hepatocyte Polarity.. Journal of Hepatology, doi:10.1016/j.jhep.2017.01.001
Harvey, K., Wetzel, A., Hughes, M., McKay, T., Waddington, S., Rahim, A. (2017). Wnt and Ca2+ signalling changes in LRRK2 Parkinson's disease models.

2016

Waddington, S.N., Privolizzi, R., Karda, R., O'Neill, H.C. (2016). A Broad Overview and Review of CRISPR-Cas Technology and Stem Cells.. Current stem cell reports, 2 9-20. doi:10.1007/s40778-016-0037-5
Suff, N., Karda, R., Perocheau, D., Delhove, J.M., McKay, T.R., Tangney, M., ...Waddington, S.N. (2016). A Light-Producing Model of Infection-Related Preterm Birth.
Suff, N., Karda, R., Perocheau, D., Delhove, J.M., McKay, T.R., Tangney, M., ...Waddington, S.N. (2016). A Light-Producing Model of Infection-Related Preterm Birth.
Henckaerts, E., Tordo, J., Palomar, N., Rahman, J., Aldrin-Kirk, P., Basche, M., ...Agbandje-McKenna, M. (2016). A Novel Rationally Designed AAV Capsid Yields a Potent Neurotropic Gene Therapy Vector.
Baruteau, J., Hanley, J., Buckley, S.M., Gissen, P., Howe, S.J., Karda, R., ...Suff, N. (2016). AAV8-mediated gene therapy rescue of lethal Argininosuccinate lyase-deficient mice..
Baruteau, J., Hanley, J., Buckley, S.M., Gissen, P., Howe, S.J., Karda, R., ...Suff, N. (2016). AAV8-mediated gene therapy rescue of lethal Argininosuccinate lyase-deficient mice..
Biermann, J., Eggers, A., Corubolo, F., Waddington, S. (2016). An ontology supporting planning, analysis, and simulation of evolving Digital Ecosystems.
Hughes, M., Smith, D., Morris, L., Tordo, J., Palomar-Martin, N., Henckaerts, E., ...Rahim, A. (2016). Development of gene therapy for Niemann-Pick Type C disease.
Karda, R., Buckley, S.M.K., Waddington, S.N. (2016). Gene Therapy with Adeno-associated Virus for Cystic Fibrosis. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 193 (3), 234-236.
Karda, R., Buckley, S.M.K., Waddington, S.N. (2016). Gene Therapy with Adeno-associated Virus for Cystic Fibrosis. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 193 (3), 234-236.
Suff, N., Karda, R., Buckley, S.M.K., Delhove, J.M., McKay, T.R., Tangney, M., ...Peebles, D. (2016). Generation of Light-Emitting Somatic-Transgenic Mice for Disease Modelling of Infection-Related Preterm Birth..
Suff, N., Karda, R., Buckley, S.M.K., Delhove, J.M., McKay, T.R., Tangney, M., ...Peebles, D. (2016). Generation of Light-Emitting Somatic-Transgenic Mice for Disease Modelling of Infection-Related Preterm Birth..
Karda, R., Perocheau, D.P., Buckley, S.M.K., Delhove, J.M.K.M., Hughes, M., Rahim, A., ...Martin, N.P. (2016). Generation of light-producing somatic-transgenic mice using adeno-associated virus vectors.
Karda, R., Perocheau, D.P., Suff, N., Ng, J., Hughes, M., Rahim, A.A., ...Henckaerts, E. (2016). Generation of light-producing somatic-transgenic mice using adeno-associated virus vectors.
Karda, R., Perocheau, D.P., Buckley, S.M.K., Delhove, J.M.K.M., Hughes, M., Rahim, A., ...Martin, N.P. (2016). Generation of light-producing somatic-transgenic mice using adeno-associated virus vectors.
Karda, R., Perocheau, D.P., Suff, N., Ng, J., Hughes, M., Rahim, A.A., ...Henckaerts, E. (2016). Generation of light-producing somatic-transgenic mice using adeno-associated virus vectors.
Karda, R., Perocheau, D.P., Buckley, S.M.K., Delhove, J.M.K.M., Hughes, M., Rahim, A.A., ...Mckay, T.R. (2016). Generation of Light-Producing, Somatic-Transgenic Mice Using Lentivirus and Adeno-Associated Virus Vectors.
Karda, R., Perocheau, D.P., Buckley, S.M.K., Delhove, J.M.K.M., Hughes, M., Rahim, A.A., ...Mckay, T.R. (2016). Generation of Light-Producing, Somatic-Transgenic Mice Using Lentivirus and Adeno-Associated Virus Vectors.
Kao, V.Y.-.C., Ferreira, S., Waddington, S.N., Antoniou, M.N. (2016). Haemophilia B Curative FIX Production from a Low Dose UCOE-based Lentiviral Vector Following Hepatic Pre-natal Delivery. CURRENT GENE THERAPY, 16 (4), 231-241. doi:10.2174/1566523216666161102150101
Massaro, G., Perocheau, D., Baker, R., Karlsson, S., Cheng, S., Waddington, S., Rahim, A. (2016). Intravenously administered gene therapy for the treatment of neuronopathic Gaucher Disease.
Migale, R., MacIntyre, D.A., Cacciatore, S., Lee, Y.S., Hagberg, H., Herbert, B.R., ...Bennett, P.R. (2016). Modeling hormonal and inflammatory contributions to preterm and term labor using uterine temporal transcriptomics. BMC MEDICINE, 14 doi:10.1186/s12916-016-0632-4
Ng, J., Zhen, J., Meyer, E., Erreger, K., Pope, S., Borck, G., ...Waddington, S.N. (2016). Novel therapeutic approaches for childhood parkinsonism.
Cuka, S., Ng, J., Seino, K., Waddington, S., Kurian, M., Rahim, A. (2016). Novel Therapeutic Strategies in NBIA: A Gene Therapy Approach for PLA2G6-associated Neurodegeneration (PLAN).
Hawkins, K.E., Joy, S., Delhove, J.M., Kotiadis, V.N., Fernandez, E., Fitzpatrick, L.M., ...Duchen, M.R. (2016). NRF2 Orchestrates the Metabolic Shift during Induced Pluripotent Stem Cell Reprogramming. Cell Reports, 14 (8), 1883-1891. doi:10.1016/j.celrep.2016.02.003
Buckinx, R., Van Remoortel, S., Gijsbers, R., Waddington, S.N., Timmermans, J.P. (2016). Proof-of-concept: neonatal intravenous injection of adeno-associated virus vectors results in successful transduction of myenteric and submucosal neurons in the mouse small and large intestine. Neurogastroenterology & Motility, 28 (2), 299-305. doi:10.1111/nmo.12724
Banushi, B., Forneris, F., Straatman-Iwanowska, A., Strange, A., Lyne, A.M., Rogerson, C., ...Doykov, I. (2016). Regulation of post-Golgi LH3 trafficking is essential for collagen homeostasis. Nature Communications, 7 doi:10.1038/ncomms12111
Migale, R., MacIntyre, D.A., Cacciatore, S., Lee, Y.S., Herbert, B.R., Waddington, S.N., ...Bennett, P.R. (2016). Relative Contribution of Hormonal and Inflammatory Pathways to Uterine Transcriptome Dynamics in Term and Preterm Labor.
Edey, L.F., O'Dea, K.P., Herbert, B.R., Hua, R., Waddington, S.N., MacIntyre, D.A., ...Johnson, M.R. (2016). The Local and Systemic Immune Response to Intrauterine LPS in the Prepartum Mouse.. Biol Reprod, 95 (6), 125. doi:10.1095/biolreprod.116.143289
Karda, R., Counsell, J.R., Vink, C.A., Perocheau, D.P., Buckley, S.M.K., Ng, J., ...Howe, S.J. (2016). Transduction of the Central Nervous System with the LTR1 Lentiviral Backbone.
Karda, R., Counsell, J.R., Vink, C.A., Perocheau, D.P., Buckley, S.M.K., Ng, J., ...Howe, S.J. (2016). Transduction of the Central Nervous System with the LTR1 Lentiviral Backbone.

2015

Karda, R., Delhove, J.M.K.M., Buckley, S.M.K., Perocheau, D.P., Rahim, A.A., Rocha-Ferreira, E., ...Hagberg, H.H. (2015). Conscious whole body bioluminescence in somatic-transgenic rodents can be used to quantify and predict brain damage in a mouse model of Cerebral Palsy.
Karda, R., Delhove, J.M.K.M., Buckley, S.M.K., Perocheau, D.P., Rahim, A.A., Rocha-Ferreira, E., ...Hagberg, H.H. (2015). Conscious whole body bioluminescence in somatic-transgenic rodents can be used to quantify and predict brain damage in a mouse model of Cerebral Palsy.
Shangaris, P., Loukogeorgakis, S., Subramanian, S., Blundell, M., Bakhamis, N., Liu, S., ...Urbani, L. (2015). Correction of Haemoglobin Levels in a Humanized Mouse Model of β-thalassemia after Fetal Gene Therapy.
Shangaris, P., Loukogeorgakis, S.P., Subramaniam, S., Blundell, M., Liu, S., Eaton, S., ...Waddington, S. (2015). Correction of Hemoglobin Levels in a Heterozygous Humanized Mouse Model of Thalassemia After Fetal Gene Therapy.
Vion-Dury, J.-.Y., Lagos, N., Kontopoulos, E., Riga, M., Mitzias, P., Meditskos, G., ...Kompatsiaris, I. (2015). Designing for Inconsistency - The Dependency-Based PERICLES Approach.
Hughes, M., Tordo, J., Massaro, G., Ng, J., Gissen, P., Waddington, S., ...Rahim, A. (2015). Development of gene therapy for Niemann-Pick type C disease.
Ng, J., Karda, R., Massaro, G., Meyer, E., Barrel, S., Baruteau, J., ...Kurian, M.A. (2015). Evaluating Promoter Regulated Dopaminergic Neuron Targeting with AAV9 Delivered To the Neonatal Mouse.
Ng, J., Karda, R., Massaro, G., Meyer, E., Barrel, S., Baruteau, J., ...Kurian, M.A. (2015). Evaluating Promoter Regulated Dopaminergic Neuron Targeting with AAV9 Delivered To the Neonatal Mouse.
Nivsarkar, M.S., Buckley, S.M., Parker, A.L., Perocheau, D., McKay, T.R., Rahim, A.A., ...Waddington, S.N. (2015). Evidence for Contribution of CD4+CD25+ Regulatory T Cells in Maintaining Immune Tolerance to Human Factor IX following Perinatal Adenovirus Vector Delivery. Journal of Immunology Research, 2015 doi:10.1155/2015/397879
Nivsarkar, M.S., Buckley, S.M., Parker, A.L., Perocheau, D., McKay, T.R., Rahim, A.A., ...Waddington, S.N. (2015). Evidence for Contribution of CD4+CD25+ Regulatory T Cells in Maintaining Immune Tolerance to Human Factor IX following Perinatal Adenovirus Vector Delivery. Journal of Immunology Research, 2015 doi:10.1155/2015/397879
Karda, R., Delhove, J.M.K.M., Buckley, S.M.K., Rahim, A.A., Rocha-Ferreira, E., Perocheau, D., ...Waddington, S.N. (2015). Generation of Light-Emitting Somatic-Transgenic Mice for Disease Modelling of Hypoxic Ischaemic Encephalopathy.
Karda, R., Delhove, J.M.K.M., Buckley, S.M.K., Rahim, A.A., Rocha-Ferreira, E., Perocheau, D.P.B., ...Waddington, S.N. (2015). Generation of Light-Emitting Somatic-Transgenic Mice for Disease Modelling of Hypoxic Ischaemic Encephalopathy.
Karda, R., Delhove, J.M.K.M., Buckley, S.M.K., Rahim, A.A., Rocha-Ferreira, E., Perocheau, D.P.B., ...Waddington, S.N. (2015). Generation of Light-Emitting Somatic-Transgenic Mice for Disease Modelling of Hypoxic Ischaemic Encephalopathy.
Buckley, S.M., Delhove, J.M., Perocheau, D.P., Karda, R., Rahim, A.A., Howe, S.J., ...Arbuthnot, P. (2015). In vivo bioimaging with tissue-specific transcription factor activated luciferase reporters. Scientific Reports, 5 doi:10.1038/srep11842
Buckley, S.M., Delhove, J.M., Perocheau, D.P., Karda, R., Rahim, A.A., Howe, S.J., ...Arbuthnot, P. (2015). In vivo bioimaging with tissue-specific transcription factor activated luciferase reporters. Scientific Reports, 5 doi:10.1038/srep11842
Massaro, G., Perocheau, D., Karlsson, S., Cheng, S.H., Waddington, S.N., Rahim, A.A. (2015). Intravenously administered gene therapy for the treatment of neuronopathic Gaucher Disease.
Migale, R., MacIntyre, D.A., Lee, Y.S., Lu, Y., Herbert, B.R., Waddington, S., ...Bennett, P.R. (2015). Mouse Myometrial Transcriptome Analysis By RNAseq Shows Inflammation Is a Side-Effect, Not a Requisite, for Labor. REPRODUCTIVE SCIENCES, 22 66A.
Counsell, J.R., Vink, C.A., Perocheau, D.P.B., Karda, R., Ng, J., Buckley, S.M.K., ...Brugman, M.H. (2015). Novel LTR-1 Lentiviral Vectors Are Fully Functional Following the Removal of HIV-1 Gag-RRE Sequences.
Counsell, J.R., Vink, C.A., Perocheau, D.P.B., Karda, R., Ng, J., Buckley, S.M.K., ...Brugman, M.H. (2015). Novel LTR-1 Lentiviral Vectors Are Fully Functional Following the Removal of HIV-1 Gag-RRE Sequences.
Counsell, J., Vink, C., Perocheau, D., Karda, R., Ng, J., Buckley, S., ...Brugman, M. (2015). Novel LTR-1 lentiviral vectors are fully functional in vitro and in vivo following the removal of HIV-1 gag-RRE sequences.
Cuka, S., Ng, J., Seino, K.-.I., Waddington, S.N., Kurian, M.A., Rahim, A.A. (2015). Novel therapeutic strategies in NBIA: A gene therapy approach for PLA2G6-associated.
Lagos, N., Waddington, S., Vion-Dury, J.-.Y. (2015). On the Preservation of Evolving Digital Content - The Continuum Approach and Relevant Metadata Models.
Buckinx, R., Van Remoortel, S., Gijsbers, R., Debyser, Z., Waddington, S., Timmermans, J.-.P. (2015). rAAV2/8 and rAAV2/9 efficiently transduce the mouse enteric nervous system after postnatal i.v. injection. NEUROGASTROENTEROLOGY AND MOTILITY, 27 47.
Delhove, J.M.K.M., Perocheau, D., Buckley, S.M.K., Karda, R., Waddington, S.N., McKay, T.R. (2015). Real-Time Monitoring of Transcription Factor Activity Using In Vitro and In Vivo Models of Cholestasis.
Delhove, J.M.K.M., Perocheau, D., Buckley, S.M.K., Karda, R., Waddington, S.N., McKay, T.R. (2015). Real-Time Monitoring of Transcription Factor Activity Using In Vitro and In Vivo Models of Cholestasis.
Pirianov, G., MacIntyre, D.A., Lee, Y., Waddington, S.N., Terzidou, V., Mehmet, H., Bennett, P.R. (2015). Specific inhibition of c-Jun N-terminal kinase delays preterm labour and reduces mortality. REPRODUCTION, 150 (4), 269-277. doi:10.1530/REP-15-0258
Migale, R., Herbert, B.R., Lee, Y.S., Sykes, L., Waddington, S.N., Peebles, D., ...MacIntyre, D.A. (2015). Specific Lipopolysaccharide Serotypes Induce Differential Maternal and Neonatal Inflammatory Responses in a Murine Model of Preterm Labor. AMERICAN JOURNAL OF PATHOLOGY, 185 (9), 2390-2401. doi:10.1016/j.ajpath.2015.05.015
Mattar, C.N., Wong, A.M., Hoefer, K., Alonso-Ferrero, M.E., Buckley, S.M., Howe, S.J., ...Rahim, A.A. (2015). Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates. The FASEB Journal, 29 (9), 3876-3888. doi:10.1096/fj.14-269092
Mattar, C.N., Wong, A.M., Hoefer, K., Alonso-Ferrero, M.E., Buckley, S.M., Howe, S.J., ...Rahim, A.A. (2015). Systemic gene delivery following intravenous administration of AAV9 to fetal and neonatal mice and late-gestation nonhuman primates. The FASEB Journal, 29 (9), 3876-3888. doi:10.1096/fj.14-269092
Ng, J., Rahim, A., Kurian, M., Waddington, S. (2015). The synapsin promoter drives expression in liver and other viscera following neonatal AAV9 injection.
Perocheau, D.P.B., Buckley, S.M.K., Delhove, J.M.K.M., Karda, R., Mckay, T.R., Waddington, S.N. (2015). Use of Somatotransgenic Bioimaging as a Platform for Studying NFkB Pathway in a Tissue-Specific Manner in Two Mouse Models of Inflammation: Rheumatoid Arthritis and Contact Dermatitis.
Perocheau, D.P.B., Buckley, S.M.K., Delhove, J.M.K.M., Karda, R., Mckay, T.R., Waddington, S.N. (2015). Use of Somatotransgenic Bioimaging as a Platform for Studying NFkB Pathway in a Tissue-Specific Manner in Two Mouse Models of Inflammation: Rheumatoid Arthritis and Contact Dermatitis.

2014

MacIntyre, D.A., Lee, Y.S., Migale, R., Herbert, B.R., Waddington, S.N., Peebles, D., ...Bennett, P.R. (2014). Activator protein 1 is a key terminal mediator of inflammation-induced preterm labor in mice.. FASEB JOURNAL, 28 (5), 2358-2368. doi:10.1096/fj.13-247783
Hughes, M.P., Howe, S.J., Buckley, S.M., Waddington, S.N., Rahim, A.A. (2014). An evaluation of viral vector-mediated gene delivery to the murine neonatal brain.
Hughes, M.P., Howe, S.J., Buckley, S.M., Waddington, S.N., Rahim, A.A. (2014). An evaluation of viral vector-mediated gene delivery to the murine neonatal brain.
Khonsari, H., Howe, S., Waddington, S., Pook, M., Themis, M. (2014). An investigation to determine the efficacy of lentivirus-mediated FXN gene delivery for the correction of Friedreich ataxia.
Ng, J., Rahim, A., Karda, R., Buckley, S., Baruteau, J., Perocheau, D., ...Waddington, S. (2014). Analysis of transduction profile of AAV2/9 tyrosine hydroxylase promoter in the neonatal mouse brain.
Shangaris, P., Loukogeorgakis, S., Subramaniam, S., Antoniou, M., Bakhamis, N., Liu, S., ...Urbani, L. (2014). Correction of haemoglobin levels in a humanized mouse model of thalassemia after fetal gene therapy.
Shangaris, P., Loukogeorgakis, S.P., Subramaniam, S., Blundell, M., Bakhamis, N., Liu, S., ...Urbani, L. (2014). Correction of Hemoglobin Levels in a Heterozygous Humanized Mouse Model of Thalassemia after Fetal Gene Therapy.
Baruteau, J., Hanley, J., Buckley, S.M., Gissen, P., Howe, S.J., Karda, R., ...Rahim, A.A. (2014). Elongation factor 1 alpha as a potential promoter for gene therapy in a murine model of both urea cycle defects and systemic disease: argininosuccinic aciduria.
Baruteau, J., Hanley, J., Buckley, S.M., Gissen, P., Howe, S.J., Karda, R., ...Rahim, A.A. (2014). Elongation factor 1 alpha as a potential promoter for gene therapy in a murine model of both urea cycle defects and systemic disease: argininosuccinic aciduria.
Chan, J., Choolani, M., Biswas, A., Johana, N., Rosales, C., McKintosh, J., ...Mattar, C. (2014). Fetal Gene Transfer in Early Gestation Promotes Stable Expression With Minimal Immune Toxicity and Facilitates Improved Expression After Postnatal Challenge.
Mattar, C., Biswas, A., Johana, N., McKintosh, J., Rosales, C., Waddington, S., ...Nathwani, A. (2014). Fetal Gene Transfer in Late Gestation Enables Stable Transgene Expression, Facilitates Postnatal Vector Re-Administration and Maintains a Good Long-Term Safety Profile.
Joerg, B., Waddington, S., Jones, R., Trowell, S. (2014). Harmonising Research Reporting in the UK - Experiences and Outputs from UKRISS.
Di Matteo, M., Samara-Kuko, E., Ward, N.J., Waddingon, S.N., McVey, J.H., Chuah, M.K.L., VandenDriessche, T. (2014). Hyperactive PiggyBac Transposons for Sustained and Robust Liver-targeted Gene Therapy. MOLECULAR THERAPY, 22 (9), 1614-1624. doi:10.1038/mt.2014.131
Rahim, A.A., Burke, D.G., Buckley, S.M., Cullen, E., Mukherji, S., Mills, K., ...Hughes, D.A. (2014). Perinatal gene therapy ameliorates a mouse model of neuronopathic Gaucher disease.
Rahim, A.A., Burke, D.G., Buckley, S.M., Cullen, E., Mukherji, S., Mills, K., ...Hughes, D.A. (2014). Perinatal gene therapy ameliorates a mouse model of neuronopathic Gaucher disease.
Karda, R., Buckley, S.M.K., Mattar, C.N., Ng, J., Massaro, G., Hughes, M.P., ...Chan, J.K.Y. (2014). Perinatal systemic gene delivery using adeno-associated viral vectors.. Front Mol Neurosci, 7 doi:10.3389/fnmol.2014.00089
Karda, R., Buckley, S.M.K., Mattar, C.N., Ng, J., Massaro, G., Hughes, M.P., ...Chan, J.K.Y. (2014). Perinatal systemic gene delivery using adeno-associated viral vectors.. Front Mol Neurosci, 7 doi:10.3389/fnmol.2014.00089
Fan, Y., Marcy, G., Lee, E.S.M., Rozen, S., Mattar, C.N.Z., Waddington, S.N., ...Chan, J.K.Y. (2014). Regionally-specified second trimester fetal neural stem cells reveals differential neurogenic programming.. PLOS ONE, 9 (9), doi:10.1371/journal.pone.0105985
Karda, R., Delhove, J.M.K.M., Buckley, S.M.K., Ward, N.J., Rahim, A.A., Herbert, B., ...Johnson, M.R. (2014). Somatic Transgenesis of the Central Nervous System for Disease Modelling and Treatment. REPRODUCTIVE SCIENCES, 21 (3), 276A-277A.
Buckley, S.M., Delhove, J.M., Karda, R., Perocheau, D., Rahim, A.A., Waddington, S.N., McKay, T.R. (2014). Somatotransgenic Bioimaging: Modelling Disease Progression or Therapeutic Amelioration By Continued Tissue-Specific Bioluminescence Imaging in Living Small Animals.
Buckley, S.M., Delhove, J.M., Karda, R., Perocheau, D., Rahim, A.A., Waddington, S.N., McKay, T.R. (2014). Somatotransgenic Bioimaging: Modelling Disease Progression or Therapeutic Amelioration By Continued Tissue-Specific Bioluminescence Imaging in Living Small Animals.
Jonuschies, J., Antoniou, M., Waddington, S., Boldrin, L., Muntoni, F., Thrasher, A., Morgan, J. (2014). The Human Desmin Promoter Drives Robust Gene Expression for Skeletal Muscle Stem Cell-Mediated Gene Therapy. CURRENT GENE THERAPY, 14 (4), 276-288. doi:10.2174/1566523214666140612154521
Condiotti, R., Goldenberg, D., Giladi, H., Schnitzer-Perlman, T., Waddington, S.N., Buckley, S.M., ...Coutelle, C. (2014). Transduction of fetal mice with a feline lentiviral vector induces liver tumors which exhibit an E2F activation signature.. MOLECULAR THERAPY, 22 (1), 59-68. doi:10.1038/mt.2013.193
Condiotti, R., Goldenberg, D., Giladi, H., Schnitzer-Perlman, T., Waddington, S.N., Buckley, S.M., ...Coutelle, C. (2014). Transduction of fetal mice with a feline lentiviral vector induces liver tumors which exhibit an E2F activation signature.. MOLECULAR THERAPY, 22 (1), 59-68. doi:10.1038/mt.2013.193
Alonso-Ferrero, M.E., Bartolovic, K., Kinnon, C., Mata, M., Waddington, S.N., Milsom, M.D., ...Howe, S.J. (2014). Transient Expression of Genes From Integrative Deficient Lentiviral Vectors Improves Blood Progenitor Cell Expansion, Survival and Engraftment.

2013

Parker, A., Lavery, C., White, K., Waddington, S., Baker, A. (2013). A chimeric, CD46 utilising vector based on Ad5/Ad35 mediates efficient ex vivo vascular gene transfer.
Dighe, N., Mattar, C., Tan, L.G., Sandikin, D., Waddington, S., Antoniou, M., ...Chan, J. (2013). Comparision of In-Utero Gene Therapy and In-Utero Hemopoietic Stem Cell Therapy Approaches in Severe Models of Murine beta Thalassemia.
Aitchison, K., Rahim, A., Reed, M., Hughes, D., Kinnon, C., Waddington, S. (2013). Developing lentiviral vectors for gene thrapy of type I Gaucher disease.
Disterer, P., Al-Shawi, R., Ellmerich, S., Waddington, S.N., Owen, J.S., Simons, J.P., Khoo, B. (2013). Exon Skipping of Hepatic APOB pre-mRNA with Splice-switching Oligonucleotides Reduces LDL Cholesterol In Vivo. Molecular Therapy, doi:10.1038/mt.2012.264
Mattar, C., Rosales, C., Fragata, R., Johana, N., Waddington, S., Biswas, A., ...Chan, J. (2013). Fetal Gene Therapy at 0.4G with AAV-hFIX or AAV-hFX Mediates Therapeutic Transgene Expression Despite Growth and a Positive Immune Response in a Non-Human Primate Model.
Mattar, C., Rosales, C., Fragata, R., Johana, N., Waddington, S., Biswas, A., ...Chan, J. (2013). Fetal Gene Therapy at Early and Late Gestation: Analysis of Outcomes and Postnatal Vector Challenge in a Macaque Model.
Rahim, A.A., Sirka, E., Burke, D.G., Buckley, S.M., Cullen, E., Mukherji, S., ...Hughes, D.A. (2013). In utero gene therapy rescue of an acute neonatal lethal mouse model of neuropathic Gaucher Disease.
Rahim, A.A., Sirka, E., Burke, D.G., Buckley, S.M., Cullen, E., Mukherji, S., ...Hughes, D.A. (2013). In utero gene therapy rescue of an acute neonatal lethal mouse model of neuropathic Gaucher Disease.
Burke, D.G., Rahim, A.A., Waddington, S.N., Karlsson, S., Enquist, I., Bhatia, K., ...Heales, S. (2013). Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes.. JOURNAL OF INHERITED METABOLIC DISEASE, 36 (5), 869-872. doi:10.1007/s10545-012-9561-3
Aitchison, K.L., Rahim, A.A., Reed, M., Burke, D.G., Hughes, D.A., Heales, S., ...Howe, S.J. (2013). Lentiviral vectors for gene therapy of type I Gaucher disease.
Osellame, L.D., Rahim, A.A., Hargreaves, I.P., Gegg, M.E., Richard-Londt, A., Brandner, S., ...Duchen, M.R. (2013). Mitochondria and quality control defects in a mouse model of Gaucher disease - links to Parkinson’s Disease. Cell Metabolism, 17 (6), 941-53.-953.. doi:10.1016/j.cmet.2013.04.014
VandenDriessche, T., Nair, N., Di Matteo, M., Petrus, I., Le Guiner, C., Blouin, V., ...Sarcar, S. (2013). Overcoming the challenges in gene therapy for haemophilia.
Karda, R., Waddington, S.N., Johnson, M.R. (2013). Perinatal Intra-Cranial Gene Transfer for Permanent Astrocyte Specific Expression in Mice.
Parker, A.L., White, K.M., Lavery, C.A., Custers, J., Waddington, S.N., Baker, A.H. (2013). Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction. GENE THERAPY, 20 (12), 1158-1164. doi:10.1038/gt.2013.44
Karda, R., Delhove, J., Buckley, S., Ward, N., McKay, T., Johnson, M., Waddington, S. (2013). Somatic transgenesis of the central nervous system for disease modelling and treatment.
Karda, R., Delhove, J.M.K.M., Buckley, S.M.K., Ward, N.J., Rahim, A.A., Herbert, B., ...Johnson, M.R. (2013). Somatic transgenesis of the central nervous system for disease modelling and treatment.
Karda, R., Delhove, J.M.K.M., Buckley, S.M.K., Ward, N.J., Rahim, A.A., Herbert, B., ...Johnson, M.R. (2013). Somatic transgenesis of the central nervous system for disease modelling and treatment.
Buckley, S.M.K., Delhove, J., Karda, R., Waddington, S.N., McKay, T.R. (2013). Somatotransgenic bioimaging: a novel biosensing platform for in vivo bioimaging.
Buckley, S.M.K., Delhove, J., Karda, R., Waddington, S.N., McKay, T.R. (2013). Somatotransgenic bioimaging: a novel biosensing platform for in vivo bioimaging.
Delhove, J., Waddington, S., Buckley, S., Karda, R., Mckay, T. (2013). Somatotransgenic bioimaging: a novel biosensing platform for in vivo bioimaging.
Mattar, C.N., Waddington, S.N., Biswas, A., Johana, N., Ng, X.W., Fisk, A.S., ...Buckley, S.M.K. (2013). Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems.. GENE THERAPY, 20 (1), 69-83. doi:10.1038/gt.2011.216
Mattar, C.N., Waddington, S.N., Biswas, A., Johana, N., Ng, X.W., Fisk, A.S., ...Buckley, S.M.K. (2013). Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems.. GENE THERAPY, 20 (1), 69-83. doi:10.1038/gt.2011.216
Cheung, W., Nowrouzi, A., Coutelle, C., Waddington, S., Bigger, B., Al Alaf, F., ...Montini, E. (2013). The fetal mouse is a model of genotoxicity that can uncover genes involved in liver cancer.
Nowrouzi, A., Cheung, W.T., Li, T., Zhang, X., Arens, A., Paruzynski, A., ...von Kalle, C. (2013). The fetal mouse is a sensitive genotoxicity model that exposes lentiviral-associated mutagenesis resulting in liver oncogenesis.. MOLECULAR THERAPY, 21 (2), 324-337. doi:10.1038/mt.2012.224
Nowrouzi, A., Cheung, W.T., Li, T., Zhang, X., Arens, A., Paruzynski, A., ...von Kalle, C. (2013). The fetal mouse is a sensitive genotoxicity model that exposes lentiviral-associated mutagenesis resulting in liver oncogenesis.. MOLECULAR THERAPY, 21 (2), 324-337. doi:10.1038/mt.2012.224
McIntosh, J., Lenting, P.J., Rosales, C., Lee, D., Rabbanian, S., Raj, D., ...McVey, J.H. (2013). Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. BLOOD, 121 (17), 3335-3344. doi:10.1182/blood-2012-10-462200
Ridley, C.M., Thur, K.E., Shanahan, J., Thillaiappan, N.B., Shen, A., Uhl, K., ...Platt, F.M. (2013). β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology.. JOURNAL OF BIOLOGICAL CHEMISTRY, 288 (36), 26052-26066. doi:10.1074/jbc.M113.463562

2012

Osellame, L.D., Rahim, A., Gegg, M.E., Waddington, S., Schapira, A.H.V., Duchen, M.R. (2012). Accumulation of damaged mitochondria in neuropathic Gaucher disease, the most prevalent risk factor for Parkinson's disease, is due to defective cellular degradation machinery.
Roybal, J.L., Endo, M., Buckley, S.M.K., Herbert, B.R., Waddington, S.N., Flake, A.W. (2012). Animal models for prenatal gene therapy: Rodent models for prenatal gene therapy. Methods in Molecular Biology, 891 201-218. doi:10.1007/978-1-61779-873-3_10
Roybal, J.L., Endo, M., Buckley, S.M.K., Herbert, B.R., Waddington, S.N., Flake, A.W. (2012). Animal models for prenatal gene therapy: rodent models for prenatal gene therapy.. Methods in molecular biology (Clifton, N.J.), 891 201-218.
Roybal, J.L., Endo, M., Buckley, S.M.K., Herbert, B.R., Waddington, S.N., Flake, A.W. (2012). Animal models for prenatal gene therapy: rodent models for prenatal gene therapy.. Methods in Molecular Biology, 891 201-218. doi:10.1007/978-1-61779-873-3_10
Roybal, J.L., Endo, M., Buckley, S.M.K., Herbert, B.R., Waddington, S.N., Flake, A.W. (2012). Animal models for prenatal gene therapy: rodent models for prenatal gene therapy.. Methods in molecular biology (Clifton, N.J.), 891 201-218.
Batten, C.A., Henstock, M.R., Bin-Tarif, A., Steedman, H.M., Waddington, S., Edwards, L., Oura, C.A.L. (2012). Bluetongue virus serotype 26: Infection kinetics and pathogenesis in Dorset Poll sheep. VETERINARY MICROBIOLOGY, 157 (1-2), 119-124. doi:10.1016/j.vetmic.2011.11.033
David, A.L., Waddington, S.N. (2012). Candidate diseases for prenatal gene therapy.. Methods in molecular biology (Clifton, N.J.), 891 9-39.
David, A.L., Waddington, S.N. (2012). Candidate diseases for prenatal gene therapy.. In (pp. 9-39). .
Coughlan, L., Waddington, S.N., Buckley, S.M., Campton, J., Custers, J., Nicklin, S.A., Baker, A.H. (2012). CD46 Does Not Affect the In Vivo Biodistribution of Species D Adenoviruses, Ad26 or Ad48 in CD46 Transgenic Mice Following IV Delivery.
Coughlan, L., Waddington, S.N., Buckley, S.M., Campton, J., Custers, J., Nicklin, S.A., Baker, A.H. (2012). CD46 Does Not Affect the In Vivo Biodistribution of Species D Adenoviruses, Ad26 or Ad48 in CD46 Transgenic Mice Following IV Delivery.
Delhove, J.M.K.M., Rahim, A.A., McKay, T.R., Waddington, S.N., Buckley, S.M.K. (2012). Choice of surrogate and physiological markers for prenatal gene therapy.. Methods in Molecular Biology, 891 273-290. doi:10.1007/978-1-61779-873-3_13
Delhove, J.M.K.M., Rahim, A.A., McKay, T.R., Waddington, S.N., Buckley, S.M.K. (2012). Choice of surrogate and physiological markers for prenatal gene therapy.. Methods in molecular biology (Clifton, N.J.), 891 273-290.
Delhove, J.M.K.M., Rahim, A.A., McKay, T.R., Waddington, S.N., Buckley, S.M.K. (2012). Choice of surrogate and physiological markers for prenatal gene therapy.. Methods in Molecular Biology, 891 273-290. doi:10.1007/978-1-61779-873-3_13
Delhove, J.M.K.M., Rahim, A.A., McKay, T.R., Waddington, S.N., Buckley, S.M.K. (2012). Choice of surrogate and physiological markers for prenatal gene therapy.. Methods in molecular biology (Clifton, N.J.), 891 273-290.
Ward, N., Buckley, S., Rahim, A., McVey, J., Thrasher, A., Waddington, S. (2012). Codon optimised FVIII constructs for treatment of haemophilia A.
Chuah, M., Rincon, M., Petrus, I., Di Matteo, M., De Bleser, P., Matrai, J., ...Samara, M. (2012). De novo and in silico design of regulatory elements for targeted and robust tissue-specific expression in gene therapy.
Aitchison, K.L., Rahim, A.A., Hughes, D., Kinnon, C., Waddington, S.N., Howe, S.J. (2012). Developing lentiviral vectors for gene therapy of Type I Gaucher Disease.
Delhove, J.M.K.M., Waddington, S.N., Ward, N.J., Jathoul, A.P., Pule, M.A., McKay, T.R., Buckley, S.M.K. (2012). Development of bicistronic lentiviral vectors for continual in vivo and endpoint analysis of gene and stem cell transfer.
Delhove, J.M.K.M., Waddington, S.N., Ward, N.J., Jathoul, A.P., Pule, M.A., McKay, T.R., Buckley, S.M.K. (2012). Development of bicistronic lentiviral vectors for continual in vivo and endpoint analysis of gene and stem cell transfer.
Mattar, C.N., Nathwani, A., Rosales, C., Waddington, S., Johana, N., Ng, X.-.W., ...Chan, J.K.Y. (2012). Early AAV-Mediated Intrauterine Gene Therapy at 0.4G in Non-Human Primates.
Rahim, A.A., Wong, A.M., Hofer, K., Buckley, S.M., Mukherji, S., Cooper, J.D., Waddington, S.N. (2012). Intravenous administration of AAV2/9 to fetal and neonatal mice leads to extensive transduction of visceral organs and intestinal epithelia.
Rahim, A.A., Wong, A.M., Hofer, K., Buckley, S.M., Mukherji, S., Cooper, J.D., Waddington, S.N. (2012). Intravenous administration of AAV2/9 to fetal and neonatal mice leads to extensive transduction of visceral organs and intestinal epithelia.
Coutelle, C., Waddington, S.N., Themis, M. (2012). Monitoring for potential adverse effects of prenatal gene therapy: mouse models for developmental aberrations and inadvertent germ line transmission.. Methods in Molecular Biology, 891 329-340. doi:10.1007/978-1-61779-873-3_15
Coutelle, C., Waddington, S.N., Themis, M. (2012). Monitoring for potential adverse effects of prenatal gene therapy: mouse models for developmental aberrations and inadvertent germ line transmission.. Methods in molecular biology (Clifton, N.J.), 891 329-340.
Mehta, V., Abi-Nader, K.N., Carr, D., Wallace, J., Coutelle, C., Waddington, S.N., ...David, A.L. (2012). Monitoring for potential adverse effects of prenatal gene therapy: use of large animal models with relevance to human application.. Methods in molecular biology (Clifton, N.J.), 891 291-328.
Mehta, V., Abi-Nader, K.N., Carr, D., Wallace, J., Coutelle, C., Waddington, S.N., ...David, A.L. (2012). Monitoring for potential adverse effects of prenatal gene therapy: use of large animal models with relevance to human application.. In (pp. 291-328). .
Ward, N.J., Buckley, S.M.K., Rahim, A.A., McVey, J.H., Waddington, S.N. (2012). Optimised Factor VIII Vectors for Gene Therapy of Haemophilia A.
Ward, N.J., Buckley, S.M.K., Rahim, A.A., McVey, J.H., Waddington, S.N. (2012). Optimised Factor VIII Vectors for Gene Therapy of Haemophilia A.
Howe, L., Malawana, J., Hua, R., Herbert, B., Waddington, S., Johnson, M. (2012). PDE Inhibitors: A Treatment for Mothers and Babies at Risk of Preterm Delivery. REPRODUCTIVE SCIENCES, 19 (S3), 358A.
Rahim, A.A., Wong, A.M., Hoefer, K., Buckley, S.M., Mattar, C.N., Chan, J.K., ...Waddington, S.N. (2012). Systemic Gene Expression after Intravenous Injection of Adeno-Associated Virus 2/9 to Fetal and Neonatal Mice.
Rahim, A.A., Wong, A.M., Hoefer, K., Buckley, S.M., Mattar, C.N., Chan, J.K., ...Waddington, S.N. (2012). Systemic Gene Expression after Intravenous Injection of Adeno-Associated Virus 2/9 to Fetal and Neonatal Mice.
Mattar, C.N., Waddington, S.N., Biswas, A., Davidoff, A.M., Choolani, M., Chan, J.K.Y., Nathwani, A.C. (2012). The case for intrauterine gene therapy. BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 26 (5), 697-709. doi:10.1016/j.bpobgyn.2012.06.006
Le Friec, G., Sheppard, D., Whiteman, P., Karsten, C.M., Shamoun, S.A.-.T., Laing, A., ...Chillakuri, C. (2012). The CD46-Jagged1 interaction is critical for human T(H)1 immunity. NATURE IMMUNOLOGY, 13 (12), 1213-+. doi:10.1038/ni.2454
Coutelle, C., Waddington, S.N. (2012). The concept of prenatal gene therapy.. Methods in Molecular Biology, 891 1-7. doi:10.1007/978-1-61779-873-3_1
Coutelle, C., Waddington, S.N. (2012). The concept of prenatal gene therapy.. Methods in molecular biology (Clifton, N.J.), 891 1-7.
Lea, S.M., Sheppard, D., Whiteman, P., le Friec, G., Waddington, S.N., Smith, R., ...Handford, P.A. (2012). The novel Jagged/1CD46 interaction: a prime target for immune modulation by viruses?.
Waddington, S., Gartner, R., Sudlow, A., Walshe, K., Scoble, R., Mitchell, L., ...Trowell, S. (2012). UKRISS - Feasibility study and proof-of-concept for a shared research information reporting service based on CERIF.
Coutelle, C., Waddington, S.N. (2012). Vector systems for prenatal gene therapy: choosing vectors for different applications.. Methods in molecular biology (Clifton, N.J.), 891 41-53.
Coutelle, C., Waddington, S.N. (2012). Vector systems for prenatal gene therapy: choosing vectors for different applications.. Methods in Molecular Biology, 891 41-53. doi:10.1007/978-1-61779-873-3_3

2011

McIntosh, J., Lenting, P., Tuddenham, E., Nawathe, S., Waddington, S., Gray, J., ...Nathwani, A. (2011). AAV mediated Factor VIII expression from a novel expression cassette with a potent codon-optimised FVIII construct. HUMAN GENE THERAPY, 22 (10), A28.
Binny, C., McIntosh, J., Peruta, M., Kymalainen, H., Tuddenham, E., Waddington, S., ...Thrasher, A. (2011). AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous haemorrhage. HUMAN GENE THERAPY, 22 (10), A45.
Nathwani, A., Binny, C.J., McIntosh, J.H., Tuddenham, E.G.D., Peruta, M.D., Kymalainen, H., ...Spence, Y. (2011). AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous haemorrhage.. Blood,
Nathwani, A., Binny, C.J., McIntosh, J.H., Tuddenham, E.G.D., Peruta, M.D., Kymalainen, H., ...Spence, Y. (2011). AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous haemorrhage.. Blood,
Ward, N.J., Buckley, S.M.K., Waddington, S.N., Vandendriessche, T., Chuah, M.K.L., Nathwani, A.C., ...Thrasher, A.J. (2011). Codon optimization of human factor VIII cDNAs leads to high-level expression.. BLOOD, 117 (3), 798-807. doi:10.1182/blood-2010-05-282707
Ward, N.J., Buckley, S.M.K., Waddington, S.N., Vandendriessche, T., Chuah, M.K.L., Nathwani, A.C., ...Thrasher, A.J. (2011). Codon optimization of human factor VIII cDNAs leads to high-level expression.. BLOOD, 117 (3), 798-807. doi:10.1182/blood-2010-05-282707
Kao, V.Y.C., Waddington, S.N., Equihua, C.M., Thrasher, A.J., Antoniou, M.N. (2011). Curative F.IX production from low-dose UCOE-lentiviral vectors. HUMAN GENE THERAPY, 22 (10), A110.
Argyros, O., Wong, S.P., Fedonidis, C., Tolmachov, O., Waddington, S.N., Howe, S.J., ...Harbottle, R.P. (2011). Development of S/MAR minicircles for enhanced and persistent transgene expression in the mouse liver. JOURNAL OF MOLECULAR MEDICINE-JMM, 89 (5), 515-529. doi:10.1007/s00109-010-0713-3
Mattar, C.N., Choolani, M., Biswas, A., Waddington, S.N., Chan, J.K.Y. (2011). Fetal gene therapy: recent advances and current challenges. EXPERT OPINION ON BIOLOGICAL THERAPY, 11 (10), 1257-1271. doi:10.1517/14712598.2011.585153
Rahim, A.A., Wong, A.M., Ahmadi, S., Hoefer, K., Buckley, S.M.K., Hughes, D.A., ...Cooper, J.D. (2011). In utero administration of Ad5 and AAV pseudotypes to the fetal brain leads to efficient, widespread and long-term gene expression.. Gene Ther., doi:10.1038/gt.2011.157
Rahim, A.A., Wong, A.M.S., Hoefer, K., Buckley, S.M.K., Mattar, C.N., Cheng, S.H., ...Waddington, S.N. (2011). Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system.. FASEB JOURNAL, 25 (10), 3505-3518. doi:10.1096/fj.11-182311
Rahim, A.A., Wong, A.M.S., Hoefer, K., Buckley, S.M.K., Mattar, C.N., Cheng, S.H., ...Waddington, S.N. (2011). Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system.. FASEB JOURNAL, 25 (10), 3505-3518. doi:10.1096/fj.11-182311
Aitchison, K.L., Rahim, A.A., Hughes, D.A., Kinnon, C., Waddington, S.N., Howe, S.J. (2011). Lentiviral vectors for gene therapy of Type I Gaucher Disease. HUMAN GENE THERAPY, 22 (10), A44.
Nathwani, A.C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., ...Jackson, S. (2011). Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.. Mol.Ther., 19 (5), 876-885. doi:10.1038/mt.2010.274
Ward, N.J., Buckley, S.M.K., Rahim, A.A., McVey, J.H., Thrasher, A.J., Waddington, S.N. (2011). Optimised vectors for the treatment of haemophilia A. HUMAN GENE THERAPY, 22 (10), A109.
Ward, N.J., Buckley, S.M.K., Rahim, A.A., McVey, J.H., Thrasher, A.J., Waddington, S.N. (2011). Optimised vectors for the treatment of haemophilia A. HUMAN GENE THERAPY, 22 (10), A109.
Mehta, V., Abi Nader, K., Waddington, S., David, A.L. (2011). Organ targeted prenatal gene therapy--how far are we?. PRENATAL DIAGNOSIS, 31 (7), 720-734. doi:10.1002/pd.2787
Rahim, A.A., Buckley, S.M.K., Chan, J.K.Y., Peebles, D.M., Waddington, S.N. (2011). Perinatal gene delivery to the CNS. Therapeutic Delivery, 2 (4), 483-491. doi:10.4155/tde.11.16
Rahim, A.A., Buckley, S.M.K., Chan, J.K.Y., Peebles, D.M., Waddington, S.N. (2011). Perinatal gene delivery to the CNS. Therapeutic Delivery, 2 (4), 483-491. doi:10.4155/tde.11.16
McKay, T.R., Rahim, A.A., Buckley, S.M.K., Ward, N.J., Chan, J.K.Y., Howe, S.J., Waddington, S.N. (2011). Perinatal gene transfer to the liver.. CURRENT PHARMACEUTICAL DESIGN, 17 (24), 2528-2541.
McKay, T.R., Rahim, A.A., Buckley, S.M.K., Ward, N.J., Chan, J.K.Y., Howe, S.J., Waddington, S.N. (2011). Perinatal gene transfer to the liver.. CURRENT PHARMACEUTICAL DESIGN, 17 (24), 2528-2541.
Shaw, S.W.S., De Coppi, P., Resca, E., Waddington, S.N., David, A.L. (2011). Prenatal congenic amniotic fluid stem cells have a higher engraftment potential for haematopoiesis than allogenic transplantation.
Buckley, S.M.K., Rahim, A.A., Chan, J.K.Y., David, A.L., Peebles, D.M., Coutelle, C., Waddington, S.N. (2011). Recent advances in fetal gene therapy. Therapeutic Delivery, 2 (4), 461-469. doi:10.4155/tde.11.17
Buckley, S.M.K., Rahim, A.A., Chan, J.K.Y., David, A.L., Peebles, D.M., Coutelle, C., Waddington, S.N. (2011). Recent advances in fetal gene therapy. Therapeutic Delivery, 2 (4), 461-469. doi:10.4155/tde.11.17
David, A.L., McIntosh, J., Peebles, D.M., Cook, T., Waddington, S., Weisz, B., ...Davidoff, A.M. (2011). Recombinant Adeno-Associated Virus-Mediated In Utero Gene Transfer Gives Therapeutic Transgene Expression in the Sheep. HUMAN GENE THERAPY, 22 (4), 419-426. doi:10.1089/hum.2010.007
Mattar, C.N., Nathwani, A.C., Waddington, S.N., Dighe, N., Kaeppel, C., Nowrouzi, A., ...Fisk, N.M. (2011). Stable Human FIX Expression After 0.9G Intrauterine Gene Transfer of Self-complementary Adeno-associated Viral Vector 5 and 8 in Macaques. Mol.Ther., 19 (11), 1950-1960. doi:10.1038/mt.2011.107
Rahim, A.A., Wong, A.M.S., Hoefer, K., Buckley, S.M.K., Mattar, C.N., Chan, J.K.Y., ...Waddington, S.N. (2011). Systemic gene expression following intravenous administration of AAV2/9 to fetal and neonatal mice and non-human primates. HUMAN GENE THERAPY, 22 (10), A106-A107.
Rahim, A.A., Wong, A.M.S., Hoefer, K., Buckley, S.M.K., Mattar, C.N., Chan, J.K.Y., ...Waddington, S.N. (2011). Systemic gene expression following intravenous administration of AAV2/9 to fetal and neonatal mice and non-human primates. HUMAN GENE THERAPY, 22 (10), A106-A107.

2010

Hristova, M., Cuthill, D., Zbarsky, V., Acosta-Saltos, A., Wallace, A., Blight, K., ...Waddington, S.N. (2010). Activation and deactivation of periventricular white matter phagocytes during postnatal mouse development. GLIA, 58 (1), 11-28. doi:10.1002/glia.20896
Hristova, M., Cuthill, D., Zbarsky, V., Acosta-Saltos, A., Wallace, A., Blight, K., ...Waddington, S.N. (2010). Activation and deactivation of periventricular white matter phagocytes during postnatal mouse development.. Glia, 58 (1), 11-28.
Hristova, M., Cuthill, D., Zbarsky, V., Acosta-Saltos, A., Wallace, A., Blight, K., ...Waddington, S.N. (2010). Activation and deactivation of periventricular white matter phagocytes during postnatal mouse development.. Glia, 58 (1), 11-28.
Buckley, S.M.K. (2010). An investigation into prenatal gene therapy for cystic fibrosis using intra-amniotic vector application to mouse models..
Binny, C.J., McIntosh, J.H., Tuddenham, E., Waddington, S., Buckley, S., Thrasher, A., ...Davidoff, A. (2010). Assessing the Potential of Perinatal Gene Transfer Using Congenital Factor VII Deficiency as a Model System.
Alba, R., Bradshaw, A.C., Coughlan, L., Denby, L., McDonald, R.A., Waddington, S.N., ...Miller, A.M. (2010). Biodistribution and retargeting of FX-binding ablated Ad5 vectors. In Press
Alba, R., Bradshaw, A.C., Coughlan, L., Denby, L., McDonald, R.A., Waddington, S.N., ...Miller, A.M. (2010). Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. BLOOD, 116 (15), 2656-2664. doi:10.1182/blood-2009-12-260026
Alba, R., Bradshaw, A.C., Coughlan, L., Denby, L., McDonald, R.A., Waddington, S.N., ...Miller, A.M. (2010). Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. BLOOD, 116 (15), 2656-2664. doi:10.1182/blood-2009-12-260026
Shaw, S.W.S., David, A.L., Antoniou, M., Meola, M., Ward, N., De Coppi, P., Waddington, S.N. (2010). Congenic Fetal Delivered Lentivirus UCOE-Luciferase Transduced Amniotic Fluid Stem Cells Preferentially Engraft in the Liver.
Ward, N.J., Buckley, S.M., Waddington, S.N., Nathwani, A.C., Tuddenham, E.G., Kinnon, C., ...McVey, J.H. (2010). Correction of Murine Hemophilia A Using SIN Lentiviral Vectors Expressing Enhanced Human Factor VIII cDNAs.
Ward, N.J., Buckley, S.M., Waddington, S.N., Nathwani, A.C., Tuddenham, E.G., Kinnon, C., ...McVey, J.H. (2010). Correction of Murine Hemophilia A Using SIN Lentiviral Vectors Expressing Enhanced Human Factor VIII cDNAs.
Wong, A.M.S., Rahim, A.A., Waddington, S.N., Cooper, J.D. (2010). Current therapies for the soluble lysosomal forms of neuronal ceroid lipofuscinosis.. BIOCHEMICAL SOCIETY TRANSACTIONS, 38 1484-1488. doi:10.1042/BST0381484
Talbot, G.E., Waddington, S.N., Bales, O., Tchen, R.C., Antoniou, M.N. (2010). Desmin-regulated Lentiviral Vectors for Skeletal Muscle Gene Transfer. MOLECULAR THERAPY, 18 (3), 601-608. doi:10.1038/mt.2009.267
Ferreira, S., Kao, V., Waddington, S., Fang, Z., Ward, N., Thrasher, A.J., Antoniou, M.N. (2010). Development of In Utero Lentiviral Vector Gene Therapy Approaches for Inherited Diseases.
Argyros, O., Wong, S.-.P., Fedonidis, C., Tolmachov, O., Waddington, S., Howe, S., ...Harbottle, R. (2010). Development of Scaffold/Matrix Attachment Region (S/MAR) Minicircles for Enhanced and Persistent Transgene Expression in the Mouse Liver.
Rahim, A.A., Wong, A.M., Hoeffer, K., Buckley, S.M., Mattar, C., Chan, J., ...Waddington, S.N. (2010). Efficient CNS, PNS, and Visceral Gene Delivery Following Fetal and Neonatal Intravenous Administration of AAV9.
Rahim, A.A., Wong, A.M., Hoeffer, K., Buckley, S.M., Mattar, C., Chan, J., ...Waddington, S.N. (2010). Efficient CNS, PNS, and Visceral Gene Delivery Following Fetal and Neonatal Intravenous Administration of AAV9.
Herbert, B.R., Sykes, L., Waddington, S.N., Johnson, M.R., Bennett, P.R. (2010). From Lights, Camera, Action!... to No Lights, Camera, and Preterm Labour!.
Othman, M., Chirinian, Y., Brown, C., Notley, C., Hickson, N., Hampshire, D., ...Baker, A. (2010). Functional characterization of a 13 bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. In Press
Othman, M., Chirinian, Y., Brown, C., Notley, C., Hickson, N., Hampshire, D., ...Baker, A. (2010). Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. BLOOD, 116 (18), 3645-3652. doi:10.1182/blood-2009-12-261131
Othman, M., Chirinian, Y., Brown, C., Notley, C., Hickson, N., Hampshire, D., ...Baker, A. (2010). Functional characterization of a 13-bp deletion (c.-1522--1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. Blood, 116 (18), 3645-3652. doi:10.1182/blood-2009-12-261131
Waddington, S., Crossley, R., Sheard, V., Howe, S., Buckley, S., Coughlan, L., ...McKay, T. (2010). Gene Delivery of a Mutant TGF beta 3 Reduces Markers of Scar Tissue Formation After Cutaneous Wounding.
Waddington, S.N., Crossley, R., Sheard, V., Howe, S.J., Buckley, S.M.K., Coughlan, L., ...McKay, T.R. (2010). Gene delivery of a mutant TGFβ3 reduces markers of scar tissue formation after cutaneous wounding.. MOLECULAR THERAPY, 18 (12), 2104-2111. doi:10.1038/mt.2010.174
Waddington, S.N., Crossley, R., Sheard, V., Howe, S.J., Buckley, S.M.K., Coughlan, L., ...McKay, T.R. (2010). Gene delivery of a mutant TGFβ3 reduces markers of scar tissue formation after cutaneous wounding.. MOLECULAR THERAPY, 18 (12), 2104-2111. doi:10.1038/mt.2010.174
Rahim, A.A., Wong, A.M.S., Buckley, S.M.K., Chan, J.K.Y., David, A.L., Cooper, J.D., ...Waddington, S.N. (2010). In utero gene transfer to the mouse nervous system.. BIOCHEMICAL SOCIETY TRANSACTIONS, 38 1489-1493. doi:10.1042/BST0381489
Rahim, A.A., Wong, A.M.S., Buckley, S.M.K., Chan, J.K.Y., David, A.L., Cooper, J.D., ...Waddington, S.N. (2010). In utero gene transfer to the mouse nervous system.. BIOCHEMICAL SOCIETY TRANSACTIONS, 38 1489-1493. doi:10.1042/BST0381489
Herbert, B., Patel, D., Waddington, S.N., Eden, E.R., McAleenan, A., Sun, X.-.M., Soutar, A.K. (2010). Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control.. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 30 (7), 1333-U151. doi:10.1161/ATVBAHA.110.204040
Mattar, C.N., AC, N., Dighe, N., Waddington, S., McIntosh, J., Biswas, A., ...Peebles, D. (2010). Late-Gestation Intravascular Delivery of Self-Complementary AAV Leads to Sustained Transgene Expression with the Possibility of Vector Integration Events in the Liver.
Al-Allaf, F.A., Coutelle, C., Waddington, S.N., David, A.L., Harbottle, R., Themis, M. (2010). LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress and perspectives.. Int Arch Med, 3 36-.
Grinshpun, A., Condiotti, R., Waddington, S., Peer, M., Zeig, E., Peretz, S., ...Giladi, H. (2010). Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus based vector. In Press
Waddington, S.N., Rahim, A.A., Mattar, C., Wong, A.M.S., Hoeffer, K., Buckley, S.M.K., ...Chan, J. (2010). Perinatal Gene Therapy for Lethal Genetic Diseases.
Waddington, S.N., Rahim, A.A., Mattar, C., Wong, A.M.S., Hoeffer, K., Buckley, S.M.K., ...Chan, J. (2010). Perinatal Gene Therapy for Lethal Genetic Diseases.
McIntosh, J., Lenting, P.J., Tuddenham, E., Sotannde, M., Waddington, S., Gray, J.T., ...Nathwani, A. (2010). Stable High Level Coagulation Factor VIII Expression In Vivo Following Gene Transfer Using a Novel Expression Cassette Encoding a More Potent FVIII Variant.
Bartolovic, K., Mongkoldhumrongkul, N., Waddington, S.N., Jayasinghe, S.N., Howe, S.J. (2010). The differentiation and engraftment potential of mouse hematopoietic stem cells is maintained after bio-electrospray.. ANALYST, 135 (1), 157-164. doi:10.1039/b917813a
Wong, A., Rahim, A., Ahmadi, S., Uwanogho, D., Waddington, S., Price, J., Cooper, J. (2010). Viral vector and neural stem cell therapies for Batten disease.

2009

Antoniou, M., Talbot, G., Waddington, S., Bales, O., Tchen, R. (2009). Desmin-regulated lentiviral vectors for skeletal muscle gene transfer.
Kennea, N.L., Waddington, S.N., Chan, J., O'Donoghue, K., Yeung, D., Taylor, D.L., ...Edwards, A.D. (2009). Differentiation of human fetal mesenchymal stem cells into cells with an oligodendrocyte phenotype. 8 (7), 1069-1079.
Parker, A.L., Waddington, S.N., Buckley, S.M.K., Custers, J., Havenga, M.J.E., van Rooijen, N., ...Baker, A.H. (2009). Effect of Neutralizing Sera on Factor X-Mediated Adenovirus Serotype 5 Gene Transfer. JOURNAL OF VIROLOGY, 83 (1), 479-483. doi:10.1128/JVI.01878-08
Parker, A.L., Waddington, S.N., Buckley, S.M.K., Custers, J., Havenga, M.J.E., van Rooijen, N., ...Baker, A.H. (2009). Effect of Neutralizing Sera on Factor X-Mediated Adenovirus Serotype 5 Gene Transfer. JOURNAL OF VIROLOGY, 83 (1), 479-483. doi:10.1128/JVI.01878-08
Rahim, A.A., Wong, A.M., Howe, S.J., Buckley, S.M., costa-Saltos, A.D., Elston, K.E., ...Anderson, P.N. (2009). Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Ther., 16 (4), 509-520.
Rahim, A.A., Wong, A.M., Howe, S.J., Buckley, S.M., costa-Saltos, A.D., Elston, K.E., ...Anderson, P.N. (2009). Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors. Gene Ther., 16 (4), 509-520.
Greig, J.A., Buckley, S.M.K., Waddington, S.N., Parker, A.L., Bhella, D., Pink, R., ...McVey, J.H. (2009). Erratum: "Influence of coagulation factor X on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors" (Molecular Theraphy (2009) 10.1038/mt.2009.152). Molecular Therapy, 17 (10), 1830-. doi:10.1038/mt.2009.186
Greig, J.A., Buckley, S.M.K., Waddington, S.N., Parker, A.L., Bhella, D., Pink, R., ...McVey, J.H. (2009). Erratum: "Influence of coagulation factor X on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors" (Molecular Theraphy (2009) 10.1038/mt.2009.152). Molecular Therapy, 17 (10), 1830-. doi:10.1038/mt.2009.186
Rahim, A.A., Wong, A.M., Buckley, S.M., Hughes, D.A., Karlsson, S., Cooper, J.D., ...Waddington, S.N. (2009). Fetal Gene Therapy for Acute Neuronopathic Gaucher Disease.
Rahim, A.A., Wong, A.M., Buckley, S.M., Hughes, D.A., Karlsson, S., Cooper, J.D., ...Waddington, S.N. (2009). Fetal Gene Therapy for Acute Neuronopathic Gaucher Disease.
Condiotti, R., Goldenberg, D., Schnitzer-Perlman, T., Waddington, S., Buckley, S., Simerzin, A., ...Galun, E. (2009). FIV-induced liver tumors harbor divergent viral integration sites, nevertheless display common gene activation patterns.
Parker, A.L., Waddington, S.N., Miller, A.M., Buckley, S.M., Nicklin, S.A., McClure, J.D., ...Baker, A.H. (2009). Genome Wide and Micro RNA Profiling of Murine Livers Following Acute Phase Intravenous Delivery of Ad5 Reveals Subsets of Hepatocyte and Kupffer Cell Regulated Genes.
Parker, A.L., Waddington, S.N., Miller, A.M., Buckley, S.M., Nicklin, S.A., McClure, J.D., ...Baker, A.H. (2009). Genome Wide and Micro RNA Profiling of Murine Livers Following Acute Phase Intravenous Delivery of Ad5 Reveals Subsets of Hepatocyte and Kupffer Cell Regulated Genes.
Alba, R., Bradshaw, A.C., Parker, A.L., Bhella, D., Waddington, S.N., Nicklin, S.A., ...McVey, J.H. (2009). Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: Effect of mutagenesis on FX interactions and gene transfer. 114 965-971.
Greig, J.A., Buckley, S.M.K., Waddington, S.N., Parker, A.L., Bhella, D., Pink, R., ...McVey, J.H. (2009). Influence of Coagulation Factor X on In Vitro and In Vivo Gene Delivery by Adenovirus (Ad) 5, Ad35 and Chimeric Ad5/Ad35 Vectors. 17 (10), 1683-1691.
Greig, J.A., Buckley, S.M.K., Waddington, S.N., Parker, A.L., Bhella, D., Pink, R., ...McVey, J.H. (2009). Influence of Coagulation Factor X on In Vitro and In Vivo Gene Delivery by Adenovirus (Ad) 5, Ad35, and Chimeric Ad5/Ad35 Vectors. MOLECULAR THERAPY, 17 (10), 1683-1691. doi:10.1038/mt.2009.152
Greig, J.A., Buckley, S.M., Waddington, S.N., Parker, A.L., Bhella, D., Pink, R., ...McVey, J.H. (2009). Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors.. MOLECULAR THERAPY, 17 (10), 1683-1691. doi:10.1038/mt.2009.152
Greig, J.A., Buckley, S.M.K., Waddington, S.N., Parker, A.L., Bhella, D., Pink, R., ...Nicklin, S.A. (2009). Influence of Factor X on In Vitro and In Vivo Gene Delivery by Ad5 and Ad35 Vectors.
Simerzin, A., Condiotti, R., Themis, M., Waddington, S.N., Galun, E. (2009). Kinetics of Transgene Expression in the Liver Following Transduction of Neonatal Mice with a Non-Primate Lentiviral Vector Indicates Selective Growth Advantage of Transduced Hepatocytes.
Condiotti, R., Goldenberg, D., Schnitzer-Perlman, T., Themis, M., Waddington, S.N., Simerzin, A., ...Galun, E. (2009). Lentiviral Transduction of Fetal Livers Induces Hepatic Tumors That Share a Specific Gene Expression Signature but Differ in Their Chromosomal Rearrangements and Viral Integration Sites.
Mattar, C.N., Dighe, N.M., Waddington, S.N., McIntosh, J., Biswas, A., Fisk, N.M., ...Chan, J. (2009). Long-Term Transgene Expression in New-Born Cynomolgus Macaques Following Intra-Uterine Gene Transfer of Self-Complementary AAV.
Ward, N.J., Apolonia, L., Cochrane, M., Buckley, S.M., Waddington, S.N., Nathwani, A.C., ...Thrasher, A.J. (2009). Nonintegrating Lentiviral Vectors for Treatment of Haemophilia B.
Ward, N.J., Apolonia, L., Cochrane, M., Buckley, S.M., Waddington, S.N., Nathwani, A.C., ...Thrasher, A.J. (2009). Nonintegrating Lentiviral Vectors for Treatment of Haemophilia B.
Hristova, M., Cuthill, D., Zbarsky, V., Acosta-Saltos, A., Wallace, A., Acosta-Saltos, F., ...Raivich, G. (2009). Periventricular Fountains of Microglia and the Down-Regulation of Microglial Activation (luring Postnatal Mouse Development.
Alba, R., Bradshaw, A.C., Parker, A.L., Bhella, D., Nicklin, S.N., Waddington, S.N., ...Barouch, D.H. (2009). Selected Modification of the Adenovirus Type 5 Hexon Modulates Interaction with Coagulation Factor X and Hepatocyte Transduction In Vivo.
Grinshpun, A., Condiotti, R., Zeig, E., Pe'er, M., Waddington, S.N., Chou, J.Y., Galun, E. (2009). Successful Neonatal Gene Therapy of Glycogen Storage Disease Type Ia Using a Feline Immunodeficiency Virus-Based Vector.
Al-Allaf, F.A., Mehmet, H., Colakogullari, M., Apostolidou, S., Waddington, S., Themis, M., Coutelle, C. (2009). Tailoring the Size of Inter-Cistronic Spacer Sequence Significantly Increases IRES-Dependent Second Gene Expression over Cap-Dependent Expression in a Bicistronic Vector: Construction of Optimized 5'-hLDLR-IRES-eGFP-3' Cassette for Gene Therapy of Familial Hypercholesterolaemia.
Pirianov, G., Waddington, S.N., Lindström, T.M., Terzidou, V., Mehmet, H., Bennett, P.R. (2009). The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J(2) delays lipopolysaccharide-induced preterm delivery and reduces mortality in the newborn mouse.. ENDOCRINOLOGY, 150 (2), 699-706. doi:10.1210/en.2008-1178
Pirianov, G., Waddington, S.N., Lindstrom, T.M., Terzidou, V., Mehmet, H., Bennett, P.R. (2009). The cyclopentone prostaglandin 15d-PGJ2 delays LPS-induced preterm delivery and reduces mortality in the new born mouse. 150 (2), 669-706.
Parker, A.L., Waddington, S.N., Buckley, S.M.K., Custers, J., Havenga, M.J.E., Rooijen, N.V., ...Baker, A.H. (2009). The effect of neutralising sera on factor X-mediated adenoviral serotype 5 gene transfer. 83 (1), 479-483.

2008

Waddington, S.N., Mcvey, J.H., Bhella, D., Parker, A.L., Barker, K., Atoda, K., ...Denby, L. (2008). A critical role for the adenovirus serotype 5 hexon in liver gene transfer.
Waddington, S.N., Mcvey, J.H., Bhella, D., Parker, A.L., Barker, K., Atoda, K., ...Denby, L. (2008). A critical role for the adenovirus serotype 5 hexon in liver gene transfer.
Waddington, S.N., McVey, J.H., Bhella, D., Parker, A.L., Barker, K., Atoda, H., ...Denby, L. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. CELL, 132 (3), 397-409. doi:10.1016/j.cell.2008.01.016
Waddington, S.N., McVey, J.H., Bhella, D., Parker, A.L., Barker, K., Atoda, H., ...Denby, L. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. CELL, 132 (3), 397-409. doi:10.1016/j.cell.2008.01.016
Parker, A.L., McVey, J.H., Waddington, S.N., Buckley, S.M.K., Francischetti, I.M.B., Monteiro, R.Q., ...Baker, A.H. (2008). An exosite within the human FX serine protease domain mediates cell transduction of AD5: FX complexes.
Parker, A.L., McVey, J.H., Waddington, S.N., Buckley, S.M.K., Francischetti, I.M.B., Monteiro, R.Q., ...Baker, A.H. (2008). An exosite within the human FX serine protease domain mediates cell transduction of AD5: FX complexes.
Ferreira, S., Waddington, S., Antoniou, M. (2008). Comparative analysis of UCOE-based lentiviral vectors in a murine neonatal intravascular delivery system.
Rahim, A.A., Waddington, S.N., Wong, A.M.S., Ward, N.J., Elston, K.E., Buckley, S.M.K., ...Thrasher, A.J. (2008). Efficient gene delivery to the adult and fetal central nervous system using pseudotyped non-integrating lentiviral vectors.
Rahim, A.A., Waddington, S.N., Wong, A.M.S., Ward, N.J., Elston, K.E., Buckley, S.M.K., ...Thrasher, A.J. (2008). Efficient gene delivery to the adult and fetal central nervous system using pseudotyped non-integrating lentiviral vectors.
David, A.L., Torondel, B., Zachary, I., Wigley, V., Abi-Nader, K., Mehta, V., ...Rodeck, C.H. (2008). Erratum: Local delivery of VEGF adenovirus to the uterine artery increases vasorelaxation and uterine blood flow in the pregnant sheep (Gene Therapy (2008) vol. 15 (1344-1350) 10.1038/sj.gt.2008.102). Gene Therapy, 15 (20), 1410-. doi:10.1038/gt.2008.157
Greig, J.A., McVey, J.H., Waddington, S.N., Parker, A.L., Buckley, S.M.K., Havenga, M.J.E., ...Baker, A.H. (2008). Factor X enhances binding and transduction of human cancer cell lines by adenovirus (Ad) serotype 5 vectors but not by Ad35.
Greig, J.A., McVey, J.H., Waddington, S.N., Parker, A.L., Buckley, S.M.K., Havenga, M.J.E., ...Baker, A.H. (2008). Factor X enhances binding and transduction of human cancer cell lines by adenovirus (Ad) serotype 5 vectors but not by Ad35.
Waddington, S.N., Buckley, S.M.K., Coutelle, C. (2008). Fetal gene therapy. (June),
Waddington, S.N., Buckley, S.M.K., Coutelle, C. (2008). Fetal gene therapy: Intervention in utero. Biochemist, 30 (3), 7-9. doi:10.1042/bio03003007
Waddington, S.N., Buckley, S.M.K., Coutelle, C. (2008). Fetal gene therapy: Intervention in utero. Biochemist, 30 (3), 7-9. doi:10.1042/bio03003007
Crossley, R., Waddington, S.N., Howe, S., Buckley, S., Reynolds, L., Sheard, V., ...Mckay, T.R. (2008). Gene delivery of latency ablated TGF-beta 3 regulates dermal wound re-epithelialization in mice and reduces factors associated with scar tissue formation.
Tuddenham, E.G., Ingerslev, J., Sorensen, L.N., Christiansen, K., Mariani, G., Peyvandi, F., ...Chuah, M.K. (2008). Genetic aspects and research development in haemostasis. HAEMOPHILIA, 14 113-118. doi:10.1111/j.1365-2516.2008.01740.x
Tuddenham, E.G., Ingerslev, J., Norengaard Sorensen, L., Christiansen, K., Mariani, G., Peyvandi, F., ...Chuah, M.K. (2008). Genetic aspects and research development in haemostasis. 14 (s3), 113-118.
Tuddenham, E.G., Ingerslev, J., Sorensen, L.N., Christiansen, K., Mariani, G., Peyvandi, F., ...Chuah, M.K. (2008). Genetic aspects and research development in haemostasis. HAEMOPHILIA, 14 113-118. doi:10.1111/j.1365-2516.2008.01740.x
Waddington, S.N., Buckley, S.M.K., Nivsarkar, M.S., Coutelle, C. (2008). Immune responses after in utero and neonatal gene transfer. In Herzog, R.W. (Ed.), Gene Therapy Immunology. John Wiley & Sons Inc..
Pirianov, G., Terzidou, V., Waddington, S., Mehmet, H., Bennett, P.R. (2008). Inhibition of c-Jun-N-terminal kinase signalling delays LPS-Induced preterm delivery and reduces mortality in the mouse.
Buckley, S.M.K., Waddington, S.N., Jezzard, S., Bergau, A., Themis, M., MacVinish, L.J., ...Coutelle, C. (2008). Intra-amniotic delivery of CFTR expressing adenovirus does not reverse Cystic Fibrosis phenotype in inbred CFTR-knockout mice.
Buckley, S.M.K., Waddington, S.N., Jezzard, S., Bergau, A., Themis, M., MacVinish, L.J., ...Coutelle, C. (2008). Intra-amniotic delivery of CFTR expressing adenovirus does not reverse Cystic Fibrosis phenotype in inbred CFTR-knockout mice.
Buckley, S.M.K., Waddington, S.N., Jezzard, S., Bergau, A., Themis, M., MacVinish, L.J., ...Coutelle, C. (2008). Intra-amniotic delivery of CFTR-expressing adenovirus does not reverse cystic fibrosis phenotype in inbred CFTR-knockout mice.. MOLECULAR THERAPY, 16 (5), 819-824. doi:10.1038/mt.2008.26
Buckley, S.M.K., Waddington, S.N., Jezzard, S., Bergau, A., Themis, M., MacVinish, L.J., ...Coutelle, C. (2008). Intra-amniotic delivery of CFTR-expressing adenovirus does not reverse cystic fibrosis phenotype in inbred CFTR-knockout mice.. MOLECULAR THERAPY, 16 (5), 819-824. doi:10.1038/mt.2008.26
Waddington, S. (2008). Laboratory developments for evaluating gene therapy.
Buckley, S.M., Howe, S.J., Sheard, V., Ward, N.J., Coutelle, C., Thrasher, A.J., ...McKay, T.R. (2008). Lentiviral transduction of the murine lung provides efficient pseudotype and developmental stage-dependent cell-specific transgene expression. Gene Ther., 15 (16), 1167-1175.
Buckley, S.M., Howe, S.J., Sheard, V., Ward, N.J., Coutelle, C., Thrasher, A.J., ...McKay, T.R. (2008). Lentiviral transduction of the murine lung provides efficient pseudotype and developmental stage-dependent cell-specific transgene expression. Gene Ther., 15 (16), 1167-1175.
David, A.L., Torondel, B., Zachary, I., Wigley, V., Abi-Nader, K., Mehta, V., ...Rodeck, C.H. (2008). Local delivery of VEGF adenovirus to the uterine artery increases vasorelaxation and uterine blood flow in the pregnant sheep (vol 15, pg 1344, 2008).
David, A.L., Torondel, B., Zachary, I., Wigley, V., Abi Nader, K., Mehta, V., ...Rodeck, C.H. (2008). Local delivery of VEGF adenovirus to the uterine artery increases vasorelaxation and uterine blood flow in the pregnant sheep.. Gene Therapy, 15 1344-1350.
Buckley, S.M., Howe, S.J., Rahim, A.A., Buning, H., McIntosh, J., Wong, S.P., ...Coutelle, C. (2008). Luciferin Detection After Intranasal Vector Delivery Is Improved by Intranasal Rather Than Intraperitoneal Luciferin Administration.. Hum.Gene Ther., 19 (10), 1050-1056.
Buckley, S.M., Howe, S.J., Rahim, A.A., Buning, H., McIntosh, J., Wong, S.P., ...Coutelle, C. (2008). Luciferin Detection After Intranasal Vector Delivery Is Improved by Intranasal Rather Than Intraperitoneal Luciferin Administration.. Hum.Gene Ther., 19 (10), 1050-1056.
Buckley, S.M., Howe, S.J., Wong, S.P., Buning, H., McIntosh, J., Baker, A., ...McKay, T.R. (2008). Luciferin detection after intra-nasal vector delivery is improved by intra-nasal rather than intra-peritoneal luciferin administration.. Hum Gene Ther, doi:10.1089/hgt.2008.023
Ward, N.J., Apolonia, L., Fernandes, C., Waddington, S.N., Cochrane, M., Nathwani, A.C., ...Philpott, N.J. (2008). Non-integrating lentiviral vector pseudotypes for safer gene therapy.
Kao, V., Waddington, S., Thrasher, A., Antoniou, M. (2008). Novel lentiviral vectors for haemophilia gene therapy.
Kao, V., Waddington, S., Thrasher, A., Antoniou, M. (2008). Novel lentiviral vectors for targeting the red blood cell lineage. HUMAN GENE THERAPY, 19 (4), 415.
Argyros, O., Wong, S.P., Niceta, M., Waddington, S.N., Howe, S.J., Coutelle, C., ...Harbottle, R.P. (2008). Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. GENE THERAPY, 15 (24), 1593-1605. doi:10.1038/gt.2008.113
Argyros, O., Wong, S.P., Niceta, M., Waddington, S.N., Howe, S.J., Coutelle, C., ...Harbottle, R.P. (2008). Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector.. Gene Therapy, 15 (24), 1593-1605. doi:10.1038/gt.2008.113
Argyros, O., Wong, S.P., Nicetta, M., Waddington, S.N., Coutelle, C., Miller, A.D., Harbottle, R.P. (2008). Persistent episomal transgene expression in liver following hydrodynamic delivery of S/MAR-Containing plasmid DNA.
Thornhill, S., Grassman, E., Ulaganathan, M., Waddington, S.N., Howe, S.J., Van der Loo, H., ...Williams, D. (2008). Self-inactivating retroviral vectors for gene therapy of SCID-X1.
Pirianov, G., Terzidou, V., Waddington, S., Lindstrom, T., Mehmet, H., Bennett, P.R. (2008). The prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J(2) delays LPS-induced preterm delivery and reduces mortality in the mouse.
Condiotti, R., Simerzin, A., Themis, M., Waddington, S., Galun, E. (2008). Time kinetics of transgene expression in the liver following transduction of neonatal mice with a non-primate lentiviral vector.
Waddington, S. (2008). Using adenovirus to deliver clotting factors: using clotting factors to deliver adenovirus.

2007

Rahim, A., Ward, N., Waddington, S., Elston, K., Cooper, J., Philpott, N., ...Raivich, G. (2007). Cell-specific gene delivery to the adult and in utero CNS using pseudotyped non-integrating lentivirus.
Hibbitt, O.C., Harbottle, R.P., Waddington, S.N., Bursill, C.A., Coutelle, C., Channon, K.M., Wade-Martins, R. (2007). Delivery and long-term expression of a 135 kb LDLR genomic DNA locus in vivo by hydrodynamic tail vein injection. 9 (6), 488-497.
Papadogiorgaki, M., Papastathis, V., Nidelkou, E., Kompatsiaris, L., Waddington, S., Bratu, B., Ribiere, M. (2007). Distributed user modeling for personalized news delivery in mobile devices.
Lenaerts, L., Baker, A.H., McVey, J.H., Waddington, S., Verbeken, E., Naesens, L. (2007). Effect of coagulation factors on liver targeting of mouse adenovirus type 1.
Waddington, S.N., Buckley, S.M., David, A.L., Peebles, D.M., Rodeck, C.H., Coutelle, C. (2007). Fetal gene transfer. Curr Opin Mol Ther, 9 432-438.
Waddington, S.N., Buckley, S.M., David, A.L., Peebles, D.M., Rodeck, C.H., Coutelle, C. (2007). Fetal gene transfer. Curr Opin Mol Ther, 9 432-438.
Parker, A.L., McVey, J.H., Doctor, J.H., Lopez-Franco, O., Waddington, S.N., Havenga, M.J.E., ...Baker, A.H. (2007). Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. JOURNAL OF VIROLOGY, 81 (7), 3627-3631. doi:10.1128/JVI.02786-06
Apolonia, L., Waddington, S., Fernandes, C., Ward, N., Bouma, G., Thrasher, A., ...Philpott, N. (2007). Long-term expression from non-integrating lentiviral vectors in muscle.
Ward, N., Apolonia, L., Fernandes, C., Waddington, S., Cochrane, M., Kinnon, C., ...Philpott, N. (2007). Non-integrating lentiviral vector pseudotypes for safer gene therapy.
Argyros, O., Wong, S.-.P., Niceta, M., Waddington, S., Coutelle, C., Miller, A., Harbottle, R. (2007). Persistent episomal transgene expression in liver following hydrodynamic delivery of S/MAR-containing plasmid DNA.
Buckley, S., Howe, S., Sheard, V., Anson, D., Parsons, D., Thrasher, A., ...McKay, T. (2007). Significant airway transduction after in utero administration of a gp64 pseudotyped lentiviral vector.
Apolonia, L., Waddington, S.N., Fernandes, C., Ward, N.J., Bouma, G., Blundell, M.P., ...Philpott, N.J. (2007). Stable Gene Transfer to Muscle Using Non-integrating Lentiviral Vectors. Mol Ther.,
Waddington, S.N., Parker, A.L., Havenga, M., Nicklin, S.A., Buckley, S.M., McVey, J.H., Baker, A.H. (2007). Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5.. Journal of Virology, 81 (17), 9568-9571. doi:10.1128/JVI.00663-07
Waddington, S.N., Parker, A.L., Havenga, M., Nicklin, S.A., Buckley, S.M., McVey, J.H., Baker, A.H. (2007). Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5.. Journal of Virology, 81 (17), 9568-9571. doi:10.1128/JVI.00663-07
Baker, A.H., Mcvey, J.H., Waddington, S.N., Di Paolo, N.C., Shayakhmetov, D.M. (2007). The influence of blood on in vivo adenovirus bio-distribution and transduction. MOLECULAR THERAPY, 15 (8), 1410-1416. doi:10.1038/sj.mt.6300206
Buckley, S.M.K., Howe, S.J., Thrasher, A., Baker, A.H., Mckay, T.R., Coutelle, C., Waddington, S. (2007). The route of luciferin administration is a critical determinant of detection of pulmonary and nasal luciferase expression by in vivo bioimaging.
Buckley, S.M.K., Howe, S.J., Thrasher, A., Baker, A.H., Mckay, T.R., Coutelle, C., Waddington, S. (2007). The route of luciferin administration is a critical determinant of detection of pulmonary and nasal luciferase expression by in vivo bioimaging.
Chan, J., Waddington, S.N., O'Donoghue, K., Kurata, H., Guillot, P.V., Gotherstrom, C., ...Fisk, N.M. (2007). Widespread distribution and muscle differentiation of human fetal mesenchymal stem cells after intrauterine transplantation in dystrophic mdx mouse. Stem Cells, 25 (4), 875-884.

2006

David, A.L.M., Peebles, D.M., Gregory, L., Waddington, S.N., Themis, M., WeiszB, R., ...C H, C. (2006). Clinically applicable procedure for gene delivery to fetal gut by ultrasound-guided gastric injection: toward prenatal prevention of early-onset intestinal diseases.. Human Gene Therapy, 17 (7), 767-769. doi:10.1089/hum.2006.17.767
Apolonia, L., Waddington, S., Collins, M., Thrasher, A., Philpott, N. (2006). Development of Non-Integrating and Site-Specifically Integrating Lentiviral Vectors. MOLECULAR THERAPY, 13 S177. doi:10.1016/j.ymthe.2006.08.527
Themis, M., Waddington, S.N., Schmidt, M., von Kalle, C., Wang, Y., Al-Allaf, F., ...Holder, M.V. (2006). Erratum: "Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice" (Molecular Therapy (2005) vol. 12 (763-771) 10.1016/j.ymthe.2005.07.358). Molecular Therapy, 13 (4), 830-. doi:10.1016/j.ymthe.2005.10.003
Themis, M., Waddington, S.N., Schmidt, M., von Kalle, C., Wang, Y., Al-Allaf, F., ...Holder, M.V. (2006). Erratum: "Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice" (Molecular Therapy (2005) vol. 12 (763-771) 10.1016/j.ymthe.2005.07.358). Molecular Therapy, 13 (4), 830-. doi:10.1016/j.ymthe.2005.10.003
Muhle, C., Neuner, A., Park, J., Pacho, F., Jiang, Q., Waddington, S.N., Schneider, H. (2006). Evaluation of prenatal intra-amniotic LAMB3 gene delivery in a mouse model of Herlitz disease. 13 (23), 1665-1676.
David, A.L., Rodeck, C.H. (2006). Gene Therapy. In van Vugt, J.M.G., Shulman, L.P. (Eds.), Prenatal Medicine. New York: Taylor & Francis.
Parker, A.L., Nicol, C.G., Waddington, S.N., Buckley, S.M., Shayakhmetov, D.M., Ni, S.H., ...Nicklin, S.A. (2006). Hepatic Tropism of Adenoviral Type 5 Vectors Can Be Mediated by Multiple Coagulation Factors.
Parker, A.L., Nicol, C.G., Waddington, S.N., Buckley, S.M., Shayakhmetov, D.M., Ni, S.H., ...Nicklin, S.A. (2006). Hepatic Tropism of Adenoviral Type 5 Vectors Can Be Mediated by Multiple Coagulation Factors.
David, A.L., Torondel, B., Zachary, I., Ramirez, M.J., Buckley, S.M., Cook, T., ...Peebles, D. (2006). Local delivery of adenovirus VEGF to the uterine arteries increases vessel relaxation and uterine artery blood flow in the sheep.
Parker, A.L., Waddington, S.N., Nicol, C.G., Shayakhmetov, D.M., Buckley, S.M., Denby, L., ...McVey, J.H. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood, 108 (8), 2554-2561. doi:10.1182/blood-2006-04-008532
Parker, A.L., Waddington, S.N., Nicol, C.G., Shayakhmetov, D.M., Buckley, S.M., Denby, L., ...McVey, J.H. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood, 108 (8), 2554-2561. doi:10.1182/blood-2006-04-008532
Parker, A.L., Waddington, S.N., Nicol, C.G., Shayakhmetov, D.M., Buckley, S.M.K., Denby, L., ...McVey, J.H. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes in vitro and in vivo. 108 (8), 2554-2561.
Parker, A.L., Waddington, S.N., Nicol, C.G., Shayakhmetov, D.M., Buckley, S.M., Denby, L., ...McVey, J.H. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes.. Blood, 108 (8), 2554-2561. doi:10.1182/blood-2006-04-008532
Parker, A.L., Waddington, S.N., Nicol, C.G., Shayakhmetov, D.M., Buckley, S.M., Denby, L., ...McVey, J.H. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes.. Blood, 108 (8), 2554-2561. doi:10.1182/blood-2006-04-008532
Themis, M., Waddington, S.N., Schmidt, M., von Kalle, C., Wang, Y., Al-Allaf, F., ...Holder, M.V. (2006). Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice (vol 12, pg 763, 2005). MOLECULAR THERAPY, 13 (4), 830. doi:10.1016/j.ymthe.2005.10.003
Themis, M., Waddington, S.N., Schmidt, M., von Kalle, C., Wang, Y., Al-Allaf, F., ...Holder, M.V. (2006). Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice (vol 12, pg 763, 2005). MOLECULAR THERAPY, 13 (4), 830. doi:10.1016/j.ymthe.2005.10.003
Themis, M., Waddington, S.N., Schmidt, M., von Kalle, C., Wang, Y.H., Al-Allaf, F., ...Holder, M. (2006). Oncogenesis following delivery of a non-primate lentiviral gene therapy vector to fetal mice.
Themis, M., Waddington, S.N., Schmidt, M., von Kalle, C., Wang, Y.H., Al-Allaf, F., ...Holder, M. (2006). Oncogenesis following delivery of a non-primate lentiviral gene therapy vector to fetal mice.
Themis, M., Waddington, S.N., Schmidt, M., von Kalle, C., Wang, Y., Al-Allaf, F., ...Holder, M. (2006). Oncogenesis Following Delivery of Lentiviral Vectors to Fetal and Neonatal Mice.
Themis, M., Waddington, S.N., Schmidt, M., von Kalle, C., Wang, Y., Al-Allaf, F., ...Holder, M. (2006). Oncogenesis Following Delivery of Lentiviral Vectors to Fetal and Neonatal Mice.
Bigger, B.W., Siapati, E.K., Mistry, A., Waddington, S.N., Nivsarkar, M.S., Jacobs, L., ...Kemball-Cook, G. (2006). Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. 13 (2), 117-126.
Bigger, B.W., Siapati, E.K., Mistry, A., Waddington, S.N., Nivsarkar, M.S., Jacobs, L., ...Kemball-Cook, G. (2006). Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX. Gene Therapy, 13 (2), 117-126.
Sun, X.M., Eden, E.R., Waddington, S.N., Soutar, A.K. (2006). Recombineering of a bacterial artificial chromosome for generation of transgenic mice expressing myc-tagged wild type or mutant (D374Y) human PCSK9.
Nathwani, A.C., Gray, J.T., Ng, C.Y., Zhou, J., Spence, Y., Waddington, S.N., ...Boon-Spijker, M. (2006). Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.. Blood, 107 (7), 2653-2661.
Thanou, M., Miller, A.D., Waddington, S. (2006). The impact of new genomic technologies: Gene Therapy. In Triggle, D.J., Taylor, J.B. (Eds.), Comprehensive Medicinal Chemistry II. Elsevier Ltd..

2005

Buckley, S.M.K., Waddington, S.N., Jezzard, S., Lawrence, L., Schneider, H., Themis, M., Coutelle, C. (2005). Factors influencing adenovirus-medated airway transduction in fetal mice. 12 (3), 484-492.
Buckley, S.M.K., Waddington, S.N., Jezzard, S., Lawrence, L., Schneider, H., Holder, M.V., ...Coutelle, C. (2005). Factors influencing adenovirus-mediated airway transduction in fetal mice. MOLECULAR THERAPY, 12 (3), 484-492. doi:10.1016/j.ymthe.2005.02.020
Buckley, S.M.K., Waddington, S.N., Jezzard, S., Lawrence, L., Schneider, H., Holder, M.V., ...Coutelle, C. (2005). Factors influencing adenovirus-mediated airway transduction in fetal mice. MOLECULAR THERAPY, 12 (3), 484-492. doi:10.1016/j.ymthe.2005.02.020
Coutelle, C., Themis, M., Waddington, S., Buckley, S., Gregory, L., Nivsarkar, M., ...Rodeck, C. (2005). Fetal gene therapy – first proofs of concept - some adverse effects. 12 (22), 1601-1607.
Coutelle, C., Themis, M., Waddington, S.N., Buckley, S.M., Gregory, L.G., Nivsarkar, M.S., ...Rodeck, C. (2005). Gene Therapy Progress and Prospects: Fetal gene therapy - first proofs of concept - some adverse effects. Gene Therapy, 12 1601-1607.
Coutelle, C., Themis, M., Waddington, S.N., Buckley, S.M.K., Gregory, L.G., Nivsarkar, M.S., ...Rodeck, C. (2005). Gene therapy progress and prospects: Fetal gene therapy - first proofs of concept - some adverse effects. GENE THERAPY, 12 (22), 1601-1607. doi:10.1038/sj.gt.3302632
Coutelle, C., Themis, M., Waddington, S.N., Buckley, S.M., Gregory, L.G., Nivsarkar, M.S., ...Rodeck, C. (2005). Gene Therapy Progress and Prospects: Fetal gene therapy - first proofs of concept - some adverse effects. Gene Therapy, 12 1601-1607.
Coutelle, C., Themis, M., Waddington, S.N., Buckley, S.M.K., Gregory, L.G., Nivsarkar, M.S., ...Rodeck, C. (2005). Gene therapy progress and prospects: Fetal gene therapy - first proofs of concept - some adverse effects. GENE THERAPY, 12 (22), 1601-1607. doi:10.1038/sj.gt.3302632
Waddington, S.N., Kramer, M.G., Hernandez-Alcoceba, R., Buckley, S.M.K., Themis, M., Coutelle, C., Prieto, J. (2005). In utero gene therapy: Current challenges and perspectives. MOLECULAR THERAPY, 11 (5), 661-676. doi:10.1016/j.ymthe.2005.01.015
Waddington, S.N., Kramer, M.G., Hernandez-Alcoceba, R., Buckley, S.M.K., Themis, M., Coutelle, C., Prieto, J. (2005). In Utero Gene Therapy: Current Challenges And Perspectives. 11 (5), 661-676.
Waddington, S.N., Kramer, M.G., Hernandez-Alcoceba, R., Buckley, S.M.K., Themis, M., Coutelle, C., Prieto, J. (2005). In utero gene therapy: Current challenges and perspectives. MOLECULAR THERAPY, 11 (5), 661-676. doi:10.1016/j.ymthe.2005.01.015
Jakob, M., Mühle, C., Park, J., Weiß, S., Waddington, S., Schneider, H. (2005). No evidence for germ-line transmission following prenatal and early postnatal AAV-mediated gene delivery. 7 (6), 630-637.
Jakob, M., Muhle, C., Park, J., Weiss, S., Waddington, S., Schneider, H. (2005). No evidence for germ-tine transmission following prenatal and early postnatal AAV-mediated gene delivery. JOURNAL OF GENE MEDICINE, 7 (5), 630-637. doi:10.1002/jgm.718
Bigger, B.W., Waddington, S.N., Jones, N., Buch, M., Jacobs, L., Perrett, R., ...Themis, M. (2005). Non-myeloablative stem cell gene delivery effectively establishes long-term gene expression and mixed chimerism in immunocompetent mice.
Themis, M., Waddington, S.N., Schmidt, M., von Kalle, C., Wang, Y.H., Al-Allaf, F., ...Holder, M.V. (2005). Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. MOLECULAR THERAPY, 12 (4), 763-771. doi:10.1016/j.ymthe.2005.07.358
Themis, M., Waddington, S.N., Schmidt, M., von Kalle, C., Wang, Y.H., Al-Allaf, F., ...Holder, M.V. (2005). Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. MOLECULAR THERAPY, 12 (4), 763-771. doi:10.1016/j.ymthe.2005.07.358
Themis, M., Waddington, S.N., Schmitt, M., Von Kalle, C., Wang, Y., Al-Allaf, F., ...Holder, M.V. (2005). Oncogenesis following delivery of a non-primate lentiviral gene therapy vector to fetal and neonatal mice. 12 (4), 763-771.
Weisz, B., David, A.L., Gregory, L.G., Perocheau, D., Ruthe, A., Waddington, S.N., ...Rodeck, C.H. (2005). Targeting the respiratory muscles of fetal sheep for prenatal gene therapy for Duchenne muscular dystrophy.. American Journal of Obstetrics and Gynecology, 193 (3pt2), 1105-1109. doi:10.1016/j.ajog.2005.06.077
Themis, M., Bennett, P.R., Mehmet, H., Waddington, S.N., Buckley, S.M. (2005). The development of a mouse model to study the effect of uterine infection on preterm labour and fetal outcome..
Themis, M., Bennett, P.R., Mehmet, H., Waddington, S.N., Buckley, S.M. (2005). The development of a mouse model to study the effect of uterine infection on preterm labour and fetal outcome..

2004

Harbottle, R., Gregory, L., Waddington, S., Coutelle, C. (2004). A mechanistic investigation of hydrodynamic mediated gene delivery.
Waddington, S. (2004). Advantages of prenatal and neonatal gene therapy - illustrated by permanent correction of haemophilia B in mice.
Bergau, A., Gregory, L., Waddington, S., Harbottle, R., Lawrence, L., Coutelle, C., Themis, M. (2004). Comparative analysis of the human cytokeratin K18 promoter with the CMV promoter by hydrodynamic injection of adult MF-1 mice.
Holder, M.V., Waddington, S.N., Gregory, L.G., Kramer, M.G., Prieto, J., Mitrophanous, K., ...Bigger, B.W. (2004). Comparison of gene expression from liver specific promoter/enhancer combinations in the context of a lentiviral backbone.
Hoare, J., Waddington, S., Thomas, H.C., Coutelle, C., McGarvey, M.J. (2004). Complement inhibition rescued mice allowing observation of transgene expression following intraportal delivery of baculovirus in mice. 7 (3), 325-333.
Waddington, S.N., Kennea, N.L., Buckley, S.M.K., Gregory, L.G., Themis, M., Coutelle, C. (2004). Fetal and neonatal gene therapy: benefits and pitfalls.
Waddington, S.N., Kennea, N.L., Buckley, S.M.K., Gregory, L.G., Themis, M., Coutelle, C. (2004). Fetal and neonatal gene therapy: benefits and pitfalls. 11 (S1), 92-97.
Waddington, S.N., Kennea, N.L., Buckley, S.M.K., Gregory, L.G., Themis, M., Coutelle, C. (2004). Fetal and neonatal gene therapy: benefits and pitfalls.
Gregory, L.G., Waddington, S.N., Holder, M.V., Mitrophanous, K.A., Buckley, S.M.K., Mosley, K.L., ...Lawrence, L. (2004). Highly efficient EIAV-mediated in utero gene transfer and expression in the major muscle groups affected by Duchenne muscular dystrophy. GENE THERAPY, 11 (14), 1117-1125. doi:10.1038/sj.gt.3302268
Gregory, L.G., Waddington, S.N., Holder, M.V., Mitrophanous, K.A., Buckley, S.M.K., Mosley, K.L., ...Lawrence, L. (2004). Highly efficient EIAV-mediated in utero gene transfer and expression in the major muscle groups affected by Duchenne muscular dystrophy. GENE THERAPY, 11 (14), 1117-1125. doi:10.1038/sj.gt.3302268
Gregory, L.G., Waddington, S.N., Holder, M.V., Mitrophanous, K.A., Buckley, S.M.K., Mosley, K.M., ...Lawrence, L. (2004). Highly efficient EIAV-mediated in utero gene transfer and expression in the major muscle groups affected by Duchenne Muscular Dystrophy.. 11 (14), 1117-1125.
Chan, J., O'Donoghue, K., Kennea, N., de la Fuente, J., Waddington, S., Themis, M., ...Fisk, N. (2004). Human fetal mesenchymal stem cells for intrauterine cellular therapy.
Bigger, B.W., Siapati, K.E., Mistry, A., Waddington, S.N., Nivsarkar, M.S., Holder, M.V., ...Forbes, S. (2004). Induction of immune tolerance and partial phenotypic correction of haermophiliac mice by lentiviral gene transfer of human factor IX to haematopoietic stem cells.
Bigger, B.W., Siapati, E.K., Mistry, A., Waddington, S.N., Nivsarkar, M.S., Holder, M.V., ...Forbes, S. (2004). Induction of immune tolerance and phenotypic rescue of hemophilic mice by stem cell mediated gene transfer.
Chan, J., O'Donoghue, K., Waddington, S., Kennea, N., Kurata, H., Guillot, P., ...Morgan, J. (2004). Myogenic differentiation and engraftment of human fetal MSC: progress towards intrauterine therapy of muscular dystrophy.
Waddington, S.N., Nivsarkar, M., Mistry, A., Buckley, S.M.K., Kemball-Cook, G., Mosley, K.L., ...Brittan, M. (2004). Permanent phenotypic correction of Haemophilia B in immunocompetent mice by prenatal gene therapy.
Waddington, S.N., Nivsarkar, M.S., Mistry, A.R., Buckley, S.M.K., Kemball-Cook, G., Mosley, K.L., ...Brittan, M. (2004). Permanent phenotypic correction of haemophilia B in immunocompetent mice by prenatal gene therapy.
Waddington, S.N., Nivsarkar, M., Mistry, A., Buckley, S.M.K., Kemball-Cook, G., Mosley, K.L., ...Brittan, M. (2004). Permanent phenotypic correction of Haemophilia B in immunocompetent mice by prenatal gene therapy.
Waddington, S.N., Nivsarkar, M.S., Mistry, A.R., Buckley, S.M.K., Kemball-Cook, G., Mosley, K.L., ...Brittan, M. (2004). Permanent phenotypic correction of haemophilia B in immunocompetent mice by prenatal gene therapy.
Waddington, S.N., Nivsarkar, M.S., Mistry, A.R., Buckley, S.M., Kemball-Cook, G., Mosley, K.L., ...Brittan, M. (2004). Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy.. Blood, 104 (9), 2714-2721. doi:10.1182/blood-2004-02-0627
Waddington, S.N., Nivsarkar, M.S., Mistry, A.R., Buckley, S.M., Kemball-Cook, G., Mosley, K.L., ...Brittan, M. (2004). Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy.. Blood, 104 (9), 2714-2721. doi:10.1182/blood-2004-02-0627
Gregory, L.G., Waddington, S.N., Holder, M., Mitrophanous, K.A., Buckley, S.M.K., Ellard, F.M., ...Kingsman, S. (2004). Pseudotyped lentiviral vectors: Toward an applicability for in utero treatment of Duchenne Muscular Dystrophy.
Gregory, L.G., Waddington, S.N., Holder, M., Mitrophanous, K.A., Buckley, S.M.K., Ellard, F.M., ...Kingsman, S. (2004). Pseudotyped lentiviral vectors: Toward an applicability for in utero treatment of Duchenne Muscular Dystrophy.
Waddington, S.N., Buckley, S.M.K., Bernloehr, C., Bossow, S., Ungerechts, G., Cook, T., ...Neubert, W.J. (2004). Reduced toxicity of F-deficient Sendai virus vector in the mouse fetus. GENE THERAPY, 11 (7), 599-608. doi:10.1038/sj.gt.3302205
Waddington, S.N., Buckley, S.M.K., Bernloehr, C., Bossow, S., Ungerechts, G., Cook, T., ...Neubert, W.J. (2004). Reduced toxicity of F-deficient Sendai virus vector in the mouse fetus. 11 (7), 599-608.
Waddington, S.N., Buckley, S.M.K., Bernloehr, C., Bossow, S., Ungerechts, G., Cook, T., ...Neubert, W.J. (2004). Reduced toxicity of F-deficient Sendai virus vector in the mouse fetus. GENE THERAPY, 11 (7), 599-608. doi:10.1038/sj.gt.3302205
Weisz, B., David, A., Peebles, D., Gregory, L., Perocheau, D., Waddington, S., ...Rodeck, C. (2004). Targeting the fetal respiratory muscles for prenatal gene therapy for Duchenne muscular dystrophy.
Nivsarkar, M.S., Nathwani, A., Mosley, K., Davies, N., Gregory, L.G., David, A.L., ...Waddington, S.N. (2004). Testosterone induced increase in transgene expression in vivo using Adenoviral Gene Delivery Vectors.
Themis, M., Gregory, L.G., Waddington, S.N., Holder, M.V., Mitrophanous, K.A., Buckley, S.M.K., ...Radcliff, P. (2004). The fetal approach: A novel therapy for the treatment of musculo-skeletal disease.
Themis, M., Gregory, L.G., Waddington, S.N., Holder, M.V., Mitrophanous, K.A., Buckley, S.M.K., ...Radcliff, P. (2004). The fetal approach: A novel therapy for the treatment of musculo-skeletal disease.
Peebles, D., Gregory, L.G., David, A., Themis, M., Waddington, S.N., Knapton, H.J., ...Nivsarkar, M. (2004). Widespread and efficient marker gene expression in the airway epithelia of fetal sheep after minimally invasive tracheal application of recombinant adenovirus in utero. GENE THERAPY, 11 (1), 70-78. doi:10.1038/sj.gt.3302130
Peebles, D.M., Gregory, L.G., David, A., Themis, M., Waddington, S.N., Knapton, H.J., ...Nivsarkar, M. (2004). Widespread and efficient marker gene expression in the airway epithelia of fetal sheep after minimally invasive tracheal application of recombinant adenovirus in utero.. Gene Therapy, 11 70-78. doi:10.1038/sj.gt.3302130
Peebles, D., Gregory, L.G., David, A., Themis, M., Waddington, S., Knapton, H.J., ...Nivsarkar, M. (2004). Widespread marker gene expression in the airway epithelia of fetal sheep after tracheal application of recombinant adenovirus in utero. 11 (1), 70-78.

2003

Waddington, S.N., Buckley, S.M.K., Cook, T., Gregory, L., Rahim, A., Nivsarkar, M., ...Lauer, U.M. (2003). Fetal gene delivery using first and second generation Sendai virus.
Waddington, S.N., Buckley, S.M.K., Cook, T., Gregory, L., Rahim, A., Nivsarkar, M., ...Lauer, U.M. (2003). Fetal gene delivery using first and second generation Sendai virus.
Themis, M., Waddington, S., Holder, M., Buckley, S., Mitrophanos, K., Bigger, B., ...Kingsman, S. (2003). Highly efficient and comprehensive gene transfer to all muscle groups necessary for the potential treatment of Duchenne/Becker muscular dystrophies following in utero delivery of a lentivirus vector in immuno-competent mice.
Waddington, S.N., Buckley, S.M.K., Nivsarkar, M., Jezzard, S., Schneider, H., Dahse, T., ...Dallman, M.J. (2003). In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. BLOOD, 101 (4), 1359-1366. doi:10.1182/blood-2002-03-0779
Waddington, S.N., Buckley, S.M.K., Nivsarkar, M., Jezzard, S., Schneider, H., Dahse, T., ...Dallman, M.J. (2003). In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. BLOOD, 101 (4), 1359-1366. doi:10.1182/blood-2002-03-0779
Waddington, S.N., Buckley, S.M., Nivsarkar, M., Jezzard, S., Schneider, H., Dahse, T., ...Dallman, M.J. (2003). In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor.. Blood, 101 (4), 1359-1366. doi:10.1182/blood-2002-03-0779
Buckley, S.M.K., Waddington, S.N., Jezzard, S., Themis, M., Colledge, W.H., Coutelle, C. (2003). Intra-amniotic application of CFTR-expressing adenovirus does not reverse cystic fibrosis phenotype in inbred Cftr-knockout mice.
Buckley, S.M.K., Waddington, S.N., Jezzard, S., Themis, M., Colledge, W.H., Coutelle, C. (2003). Intra-amniotic application of CFTR-expressing adenovirus does not reverse cystic fibrosis phenotype in inbred Cftr-knockout mice.
Azzouz, M., Le, T.N., Waddington, S., Walmsley, L., Monani, U., Wilkes, F.J., ...Mazarakis, N.D. (2003). Lentiviral vector-mediated gene therapy for a mouse model of spinal muscular atrophy.
Waddington, S.N., Mitrophanous, K.A., Ellard, F.M., Buckley, S.M.K., Nivsarkar, M., Lawrence, L., ...Kingsman, S.M. (2003). Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice. GENE THERAPY, 10 (15), 1234-1240. doi:10.1038/sj.gt.3301991
Waddington, S.N., Mitrophanous, K.A., Ellard, F., Buckley, S.M.K., Nivsarkar, M., Lawrence, L., ...Kingsman, S. (2003). Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice. 10 (15), 1234-1240.
Waddington, S.N., Mitrophanous, K.A., Ellard, F.M., Buckley, S.M.K., Nivsarkar, M., Lawrence, L., ...Kingsman, S.M. (2003). Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice. GENE THERAPY, 10 (15), 1234-1240. doi:10.1038/sj.gt.3301991
David, A.L., Themis, M., Waddington, S.N., Gregory, L., Buckley, S.M.K., Nivsarkar, M., ...Coutelle, C. (2003). The current status and future directions of fetal gene therapy. 7 181-209.
Coutelle, C., Themis, M., Waddington, S., Gregory, L., Nivsarkar, M., Buckley, S., ...David, A. (2003). The hopes and fears of in utero gene therapy for genetic disease - a review. Placenta, 24 S114-S121.
Coutelle, C., Themis, M., Waddington, S., Gregory, L., Nivsarkar, M., Buckley, S., ...David, A. (2003). The hopes and fears of in utero gene therapy for genetic disease - A review. Placenta, 24 (SUPPL. B), doi:10.1016/S0143-4004(03)00140-1
Coutelle, C., Themis, M., Waddington, S., Gregory, L., Nivsarkar, M., Buckley, S., ...David, A. (2003). The hopes and fears of in utero gene therapy for genetic disease - A review. Placenta, 24 (SUPPL. B), doi:10.1016/S0143-4004(03)00140-1
Coutelle, C., Themis, M., Waddington, S., Gregory, L., Nivsarkar, M., Buckley, S., ...David, A. (2003). The hopes and fears of in utero gene therapy for genetic disease--a review. 24 Suppl B S114-S121.
David, A., Cook, T., Waddington, S., Peebles, D., Nivsarkar, M., Knapton, H., ...Schneider, H. (2003). Ultrasound guided percutaneous delivery of adenoviral vectors encoding the beta-galactosidase and human factor IX genes to early gestation fetal sheep in utero. 14 (4), 353-364.
David, A.L.M., Cook, T., Waddington, S., Peebles, D., Nivsarkar, M., Knapton, H., ...Schneider, H. (2003). Ultrasound guided percutaneous delivery of adenoviral vectors encoding the beta-galactosidase and human factor IX genes to early gestation fetal sheep in utero. Human Gene Therapy, 14 353-364. doi:10.1089/104303403321208952
Gregory, L.G., Peebles, D., David, A., Themis, M., Waddington, S.N., Knapton, H.J., ...Nivsarkar, M. (2003). Widespread and efficient adenovirus-mediated gene transfer to the airways by DEAE dextran and sodium caprate in adult mice and fetal sheep after minimally invasive tracheal application.

2002

Waddington, S.N. (2002). Arginase in glomerulonephritis. 61 (3), 876-881.
Schneider, H., Mühle, C., Douar, A.M., Waddington, S., Jiang, Q., Mark, K.V.D., ...Rascher, W. (2002). Sustained delivery of therapeutic concentrations of human clotting factor IX - a comparison of adenoviral and AAV vectors administered in utero. 4 46-53.

2000

Waddington, S.N., Cattell, V. (2000). Arginase in glomerulonephritis.. EXPERIMENTAL NEPHROLOGY, 8 (3), 128-134.

1999

Waddington, S., Cook, T., Ebrahim, H., Mosley, K., Cattell, V. (1999). Antioxidant treatment suppresses injury and iNOS induction in Thy 1 glomerulonephritis (gn)..
Waddington, S.N., Cattell, V. (1999). Arginase in glomerulonephritis. 2000 (8), 128-134.
Waddington, S.N., Mosley, K., Cattell, V. (1999). Induced nitric oxide (NO) synthesis in heterologous nephrotoxic nephritis; effects of selective inhibition in neutrophil-dependent glomerulonephritis. 118 (2), 309-314.
Mosley, K., Waddington, S.N., Ebrahim, H., Cook, T., Cattell, V. (1999). Inducible nitric oxide synthase induction in thy 1 glomerulonephritis is complement and reactive oxygen species dependent. 7 (1), 26-34.
Cattell, V., Cook, H.T., Ebrahim, H., Waddington, S., Assman, K.J.J.M., Wei, X., Liew, F.Y. (1999). Lack of inducible nitric oxide synthase does not affect accelerated anti-GMB glomerulonephritis in the mouse..

1998

Cattell, V., Cook, H.T., Ebrahim, H., Waddington, S.N., Wei, X., Assman, K.J.M., Liew, F.Y. (1998). Anti-GBM glomerulonephritis in mice lacking nitric oxide synthase type 2. 53 932-936.
Waddington, S.N., Tam, F.W.K., Cook, H.T., Cattell, V. (1998). Arginase activity is modulated by IL-4 and HOArg in nephritic glomeruli and mesangial cells. 274 (3), F473-F480.
Waddington, S.N., Tam, F.W.K., Cook, H.T., Cattell, V. (1998). Arginase activity is modulated by IL-4 and HOArg in nephritic glomeruli and mesangial cells. American Journal of Physiology - Renal Physiology, 274 (3 43-3), doi:10.1152/ajprenal.1998.274.3.f473
Waddington, S.N., Tam, F.W., Cook, H.T., Cattell, V. (1998). Arginase activity is modulated by IL-4 and HOArg in nephritic glomeruli and mesangial cells.. The American journal of physiology, 274 (3), F473-F480. doi:10.1152/ajprenal.1998.274.3.f473
Waddington, S.N., Mosley, K., Cook, H.T., Tam, F.W.K., Cattell, V. (1998). Arginase AI is upregulated in acute immune complex-induced inflammation. 247 84-87.

1997

Waddington, S.N., Cattell, V., Cook, H.T. (1997). Arginase activity in nephritic glomeruli is inhibited by hydroxyarginine (HOArg) and increased by IL-4.

1996

Waddington, S., Cook, H.T., Reaveley, D., Jansen, A., Cattell, V. (1996). L-Arginine depletion inhibits glomerular nitric oxide synthesis and exacerbates rat nephrotoxic nephritis.. 49 1090-1096.

1994

COOK, T., WADDINGTON, S., JANSEN, A., CATTELL, V. (1994). ARGINASE REDUCES NITRIC-OXIDE (NO) SYNTHESIS BY GLOMERULI IN NEPHROTOXIC NEPHRITIS (NTN) AND EXACERBATES PROTEINURIA AND GLOMERULAR THROMBOSIS.

1991

Elliott, C.J.H., Kemenes, G., Waddington, S. (1991). The modulatory peptide SCPb inhibits feeding in the mollusc Lymnaea stagnalis. 100C (3), 615-618.
ELLIOTT, C.J.H., KEMENES, G., WADDINGTON, S. (1991). THE MODULATORY PEPTIDE SCPB INHIBITS FEEDING IN THE MOLLUSK, LYMNAEA-STAGNALIS. COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-PHARMACOLOGY TOXICOLOGY & ENDOCRINOLOGY, 100 (3), 615-618. doi:10.1016/0742-8413(91)90049-Y

1900

Baruteau, J.C. (1900). A gene therapy approach for Argininosuccinic aciduria. (Doctoral Dissertation). University College London.
Privolizzi, R., Tijani, M., Giardina, E., Cooper, S., Oosterveen, T., Iglesias, J.M., ...Ng, J. (1900). In vivo evaluation of novel synthetic promoters for CNS gene therapy. Presented at: European Society for Gene and Cell Therapy (ESGCT) Edinburgh, UK.
Massaro, G. (1900). Intravenously administered gene therapy for neuronopathic Gaucher disease. (Doctoral Dissertation). UCL.
Abi Nader, K., David, A.L. (1900). Prenatal Gene Therapy. In Reproductive Genetics. London: RCOG Press.